Upload
vobao
View
220
Download
0
Embed Size (px)
Citation preview
Policy Number LCH-140
This document has been reviewed in line with the Policy Alignment Process for Liverpool Community Health NHS Trust Services. It is a valid Mersey Care document, however due to organisational change this FRONT COVER has been added so the reader is aware of any changes to their role or to terminology which has now been superseded. When reading this document please take account of the changes highlighted in Part B and C of this form.Part A – Information about this Document
Policy NameClinical Guidelines Intravenous Access Care and Maintenance for Adult Patients in hospital and at home
Policy Type Board Approved (Trust-wide) ☐ Trust-wide ☐ Divisional / Team / Locality ☒
Action No Change ☐ Minor
Change ☐ MajorChange ☐ New
Policy ☒ No LongerNeeded ☐
Approval
As Mersey Care’s Executive Director / Lead for this document, I confirm that this document:a) complies with the latest statutory / regulatory requirements,b) complies with the latest national guidance,c) has been updated to reflect the requirements of clinicians and officers, andd) has been updated to reflect any local contractual requirements
Signature: Date:Part B – Changes in Terminology (used with ‘Minor Change’, ‘Major Changes’ & ‘New Policy’ only)
Terminology used in this Document New terminology when reading this Document
Part C – Additional Information Added (to be used with ‘Major Changes’ only)Section /
Paragraph NoOutline of the information that has been added to this document – especially where it may
change what staff need to do
Part D – Rationale (to be used with ‘New Policy’ & ‘Policy No Longer Required’ only)Please explain why this new document needs to be adopted or why this document is no longer required
Part E – Oversight Arrangements (to be used with ‘New Policy’ only)Accountable Director
Recommending Committee
Approving Committee
Next Review Date
LCH Policy Alignment Process – Form 1
SUPPORTING STATEMENTS This document should be read in conjunction with the following statements:
SAFEGUARDING IS EVERYBODY’S BUSINESSAll Mersey Care NHS Foundation Trust employees have a statutory duty to safeguard and promote the welfare of children and adults, including: being alert to the possibility of child / adult abuse and neglect through their observation of
abuse, or by professional judgement made as a result of information gathered about the child / adult;
knowing how to deal with a disclosure or allegation of child / adult abuse; undertaking training as appropriate for their role and keeping themselves updated; being aware of and following the local policies and procedures they need to follow if they
have a child / adult concern; ensuring appropriate advice and support is accessed either from managers, Safeguarding
Ambassadors or the trust’s safeguarding team; participating in multi-agency working to safeguard the child or adult (if appropriate to your
role); ensuring contemporaneous records are kept at all times and record keeping is in strict
adherence to Mersey Care NHS Foundation Trust policy and procedures and professional guidelines. Roles, responsibilities and accountabilities, will differ depending on the post you hold within the organisation;
ensuring that all staff and their managers discuss and record any safeguarding issues that arise at each supervision session
EQUALITY AND HUMAN RIGHTSMersey Care NHS Foundation Trust recognises that some sections of society experience prejudice and discrimination. The Equality Act 2010 specifically recognises the protected characteristics of age, disability, gender, race, religion or belief, sexual orientation and transgender. The Equality Act also requires regard to socio-economic factors including pregnancy /maternity and marriage/civil partnership.
The trust is committed to equality of opportunity and anti-discriminatory practice both in the provision of services and in our role as a major employer. The trust believes that all people have the right to be treated with dignity and respect and is committed to the elimination of unfair and unlawful discriminatory practices.
Mersey Care NHS Foundation Trust also is aware of its legal duties under the Human Rights Act 1998. Section 6 of the Human Rights Act requires all public authorities to uphold and promote Human Rights in everything they do. It is unlawful for a public authority to perform any act which contravenes the Human Rights Act.
Mersey Care NHS Foundation Trust is committed to carrying out its functions and service delivery in line the with a Human Rights based approach and the FREDA principles of Fairness, Respect, Equality Dignity, and Autonomy
Clinical Guidelines
For NHS North West
Intravenous AccessCare and Maintenance for Adult
PatientsIn Hospital and at Home
Developed byCollaborative Intravenous Nursing
Service (CINS)
If you would like further information about using these guidelines, contact Mrs A Young 0151 706 3650
Version 11
Issue date September 2014 Review date due September 2016
the works herein in accordance with the Data Protection Act 1988.Policy review date 01/09/16
1Index Page
Background and Objectives 2
Terms of Reference 3
STC1 Care and Maintenance of a Skin Tunnelled Catheter 4
STC2 Skin Tunnelled Catheters - Saline Flush and Hepsal Lock 6
STC3 Skin Tunnelled Catheters – Blood sampling 9
STC4 Skin Tunnelled Catheters – Administration of antibiotics/infusion/additives 12
CVC1 Care and Maintenance of a non tunnelled Central Venous Catheter 17
CVC2 Central Non-Tunnelled Catheters - Saline Flush and Hepsal Lock 19
CVC3 Central Non-Tunnelled Catheters – Blood Sampling 22
CVC4 Central Venous Non-Tunnelled Catheters – Administration of antibiotics/infusion/ Additives
25
PL1 Care and Maintenance of a Peripheral Inserted Central Catheter (PICC) 30
PL2 Peripherally Inserted Central Catheter – Sodium Chloride Saline Flush 33
PL3 Peripherally Inserted Central Catheter – Blood Sampling 36
PL4 Peripherally Inserted Central Catheter – Administration of antibiotics/infusion/ additives
39
PM1 Care and Maintenance of a Peripheral Midline Catheter 45
PM2 Peripheral Midline - Saline Flush and Hepsal Lock 47
PM3 Peripheral Midline – Administration of antibiotics/infusion/additives 50
DST1 Disconnection of Ambulatory Chemotherapy Infusor from Central Venous Access Device
54
TIVAD1 Care and Management of an Implantable Venous Access Device 57
TIVAD2 Care and Management of an Implantable Venous Access Device 60
TIVAD3 Administration of antibiotics/infusion/additives via implantable port 63
PCN1 Care and Management of Peripheral cannula 66
NFS1 Changing a needle-free system 69
Trouble Shooting Guides 70
Care Plans 74
Appendix/ContributorsThe CINs group hereby assert their moral rights to 94
2
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Intravenous Access Care and MaintenanceBackground
“Every effort has been made to present accurate and up to date
information from the best and most reliable sources. However, the results
of caring for individuals depend on a variety of factors not under the
control of the authors of these documents. Therefore, neither the authors
nor any publishers assume responsibility for, nor make any warranty with
respect to the outcomes achieved from the guidance herein”.
The service provision for patients who require intravenous care and management has been
variable with no universally agreed competency based framework. It has been extremely
difficult for district nurses to obtain clarity about which protocol/procedures they should follow.
Several guidelines can be in circulation at any one time from different Trusts. As a result of
these inconsistencies the Collaborative Intravenous Nursing Service (CINS) was formed to
gained consensus for universally agreed guidelines, competencies, care plans and resources
for the Cheshire and Merseyside strategic Health Authority. The CINS group has since
developed into a network of lead nurses, key experts and others with a specific interest in IV
therapy. These leads have contributed to the development of these guidelines and have
consulted locally with key experts.
Key Objectives
To provide universal guidelines for care and maintenance of venous access devices, care plans and troubleshooting guidelines for members of the CINS network.
To provide a competency framework for individuals in caring and maintaining venous access devices
To provide a training programme.
To ensure that those individuals caring for venous access devices have received an annual update.
To develop an expert group that will ensure that the best evidence based practice is available.
3
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
CINS NetworkVenous Access Clinical GroupTerms of Reference
The purpose of the group is to ensure that all nurses with relevant competencies across Cheshire CINS network utilise universal guidelines, competencies and training.
To act as the primary source of advice on issues relating to the care and maintenance of venous access devices (VADs).
To provide a resource for the implementation, co-ordinated procedures and guidelines across the CINS network
To promote consistent clinical competencies for VADs across the CINS Network.
To collaborate with workforce and education stakeholders to promote consistent clinical competencies and ensure the availability of the VAD training programmes.
To ensure that there is a network of support for nurses involved in IV therapy.
To ensure that in development of CINS resources appropriate consultation across multi-agencies and multi-professional groups is sought.
Membership
All Hospital Trusts, Primary Care organisations and other relevant stakeholders within Cheshire and Merseyside North West Strategic Health Authority were invited to take part in the development of these guidelines.
All healthcare professions with an interest in IV therapy who are members of the CINs network.
Chair/Reporting
The chair will be a member of the group who is dually elected. The group will report to the Directors of Nursing Group within the region and to NHS North West.
Use of the Guidelines
This document contains several guidelines which can be utilised as required.
4
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Care and Maintenance of a Skin Tunnelled Catheter (STC1)
EXIT DRESSING CHANGE (Weekly)
A
ction RationaleEquipment r e quired
Dressing Pack containing sterile towel and Gloves Surgical tape2% Chlorhexidine in 70% Isopropyl alcohol impregnated applicator ( SEPP) Chlorhexidine 2% wipe (e.g. sani cloth)Skin fixation device (e.g. Stat lock or grip lock) Semi- Permeable transparent IV dressing Alcohol hand rub or gelPlastic apron
Care of E x it site Dressing changes should be performed on a weekly basis or when dressing is dirty or loose. Explain the procedure to the patient. Ensure that valid consent is gained. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times.
To prevent/reduce patient anxiety.
To prevent infection.
Ensure working area is clean. Ensure all equipment is gathered before commencing the procedure and all packaging
is intact and in date. Take equipment/trolley to patient.
Maintain safety.
To prevent infection and catheter contamination.
5
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g. exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble- shooting guide.
Exit site dressings are important in preventing trauma and the extrinsic contamination of the site of entry (Jones 2004).
Decontaminate hands Open sterile pack and use a non-touch technique to place inner pack onto clean
working area. Open out sterile pack to create an aseptic field. Open remaining equipment using
a non touch technique, ensuring no contamination of aseptic field.
Loosen exit site dressing. To loosen dressing lift lower-end and gently ease the dressing off, from the skin using an aseptic technique.
To avoid contamination of aseptic field. To allow for an aseptic environment for accessing intravenous catheter,and to reduce incidence of infection. Chlorhexidine-based solutions are recommended (in alcohol) as per policy (DOH 2001).To prevent accidental removal of the catheter and friction or trauma to skin surface.
Decontaminate hands Put on sterile gloves Place sterile towel as near as possible to the catheter. Clean around the catheter and exit site with Chlorhexidine 2% impregnated applicator. The solution should be applied with friction but should not be too vigorous or the
skin's natural defence may be destroyed. Using a Chlorhexidine 2% wipe, carefully clean the catheter from the exit site to
the part of the catheter that will be covered by the sterile dressing. Allow to dry. Apply new securing device i.e. Skin closure strips or skin fixation device (if required) Apply new dressing to exit site without touching the adhesive site. Remove the dressing towel Remove gloves. Clear away equipment disposing of waste as per organisational policy. Wipe down the
trolley if used during the procedure with multi-surface detergent wipes. Wash hands. Document care on patient’s records.
Alcohol Chlorhexidine combines the benefits of rapid action and excellent residual activity (DOH 2001)
Semi-permeable transparent IV dressings are well tolerated by patients (Campbell et al 1999, Treston-Aurand et al 1997, Wille 1993) and are easy to apply and remove (Wille 1997).
6
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Skin Tunnelled Catheters – 0.9% Sodium Chloride and Heparin 10 units/ml in 0.9% Sodium Chloride for injection Lock (STC2) for weekly maintenance Flush
Action Rationale
Equipment Required
Dressing Pack containing sterile towel and glovesChlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated wipe (sani cloth) x 310ml syringe x 2 (1 if using a prefilled saline syringe)10ml 0.9% Sodium Chloride (or 0.9% Sodium Chloride prefilled syringe) 5ml Heparin 10units/ml in 0.9% Sodium ChlorideOne blue needle/filter straw (for glass ampoules). Sharps containerSurgical tape Alcohol hand rub/gel Plastic apron
Needle free I/V access connector change as per manufacturer’s guidelines see NSF1 Cins guideline
NB. 5ML HEPARIN SODIUM (10 UNITS/ML)FOR OPEN ENDED CATHETER
10ml syringes should always be used; smaller syringe sizes may damage the catheter (Hadaway 1998).
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust
policy for the administration of medications. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times.
Reduce anxiety Patient compliance
Maintain asepsis and safety. Reduce risk of infection.To avoid contamination.To ensure that the procedure can be
7
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Ensure working area is clean. Ensure all equipment is gathered before commencing the procedure and all
packaging is intact and in date. Take equipment/trolley to patient. Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g.
exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble- shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using a
non-touch technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline and
place near to but not on the sterile field. Ensure easy access to the needle free system. Decontaminate hands. Put on sterile gloves. Connect needle/ filter straw to the syringe. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe and place on sterile field. Place sterile towel as near as possible to the catheter Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe over a period of 30 seconds. Allow to dry.
Attach syringe with 0.9% Sodium Chloride flush and inject the flush using a push/pause action, clamping as the last ml of solution is instilled into the catheter.
Remove the syringe and discard. If open ended skin tunnelled catheter repeat this procedure using syringe containing 5ml Heparin 10units/ml in 0.9% Sodium Chloride.
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can damage the
carried out safely.
To maintain a sterile field.
Chlorhexidine-based solutions are recommended (in alcohol) as per policy (DOH 2001).
There is no requirement to routinely withdraw blood and discard it prior to flushing (except prior to blood sampling although the first sample can be used for
8
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide or contact the hospital team who placed the catheter for advice.
Wrap the end of the line in sterile gauze (gauze cot). Tape this to the patients’ chest. Ensure that the catheter is secure and comfortable.
Remove dressing towel and discard. Remove gloves. Wash hands. Clear away equipment disposing of sharps and waste as per organisational policy.
Wipe down the trolley (if used) with multi-surface detergent wipes Decontaminate hands Document care in patient’s records.
blood cultures (RCN 2010).
There is an increased risk of infection and occlusion when withdrawing blood via a central venous catheter (RCN 2010), therefore for routine flushing of a line withdrawal of blood is not required.
The pulsated flush creates turbulence within the catheter lumen, removing debris from the internal catheter wall (Goodwin & Carlson 1993, Todd 1998).
Positive pressure within the lumen of the catheter should be maintained to prevent reflux of blood (INS 2000)
9
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Skin Tunnelled Catheters – Blood Sampling (STC3)
Action RationaleEquipment Required
Dressing Pack containing sterile towel and glovesChlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated wipe (Sani Cloth) x 310ml syringes x 4 (or appropriate size syringe to collect the blood sample) 10ml 0.9% Sodium Chloride for injection prefilled syringe (or a 10ml ampoule of 0.9% Sodium Chloride)5ml Heparin10units/ml in 0.9% Sodium Chloride One blue needle/filter straw.Sharps container Surgical tape Alcohol hand rub/gel Plastic apronNeedle free I/V access connector change as per manufacturer’s guidelines see NSF1 Cins guideline
NB 5ML HEPARIN 10 UNITS/ML IN SODIUM CHLORIDE WITH OPEN ENDED CATHETER
10 ml syringes should always be used. Smaller syringe sizes may damage the
catheter (Hadaway 1998)
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust
policy for the administration of medications. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times.
Reduce anxiety Patient complianceTo ensure that the procedure can be carried out safely.
Reduce risk of infection To avoid contamination
10
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packaging
is intact and in date. Take equipment /trolley to patient. Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g.
exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble- shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using
a non touch technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline and
place near to but not on the sterile field. Ensure easy access to the needle free system. Decontaminate hands. Put on sterile gloves. Connect needle/ filter straw to the syringe. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe and place on sterile field. Place sterile towel as near as possible to the catheter. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Attach empty 10ml syringe into needle free system and aspirate at least 3 to 5ml of blood from the catheter. Note if taking blood samples from a parenteral nutrition line or for INR sample at least 10-20mls of blood should be taken and disguarded before taking the sample (check local policy). If unable aspirate blood from the line attach the syringe containing the saline solution to the needle free system gently flush with 1-2mls
To maintain a sterile field.
Chlorhexidine-based solutions are recommended (in alcohol) as per policy (DOH 2001).
Check catheter patency. Remove any residual solution from catheter.
11
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
0.9% Sodium Chloride for injection (do not use force) then aspirate blood from catheter. Discard blood aspirated as per policy
Attach an empty syringe and withdraw amount of blood required for analysis. Attach syringe with 0.9% Sodium Chloride for injection flush and inject the flush using
a push/pause action, clamping as the last ml of solution is instilled into the catheter. Remove the syringe and discard. If open ended skin tunnelled catheter repeat this
procedure using 5ml Heparin 10units/ml in 0.9% Sodium Chloride for injection. NEVER FORCE THE SOLUTION INTO THE CATHETER, this can damage the
catheter. The solution should flow easily. If resistance is felt refer to the trouble shooting guide or contact IV access team.
Wrap the end of the line in sterile gauze (gauze cot). Tape this to the patients’ chest. Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves and apron. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the
trolley that has been used during the procedure with multi-surface detergent wipes. Wash hands Document care in patient’s records.
The pulsated flush creates turbulence within the catheter lumen, removing debris from the internal catheter wall (Goodwin & Carlson 1993, Todd 1998).
Positive pressure within the lumen of the catheter should be maintained to prevent reflux of blood (INS 2000).
12
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Skin Tunnelled Catheters – Administration of IV medications/infusion (STC4)Administer drugs or IV therapy as prescribed using correct diluent and rate of infusion. Always use 10ml syringe, never use force to flush the catheter.
A ction RationaleEquipment Required
Dressing pack containing sterile towel and glovesChlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated wipe 10ml syringes x 42 x 10ml 0.9% Sodium Chloride for injection prefilled syringes (or 2 x 10mls 0.9% Normal Saline ampoules)5ml Heparin10units/ml in 0.9% Sodium Chloride for injection Two blue needle/ filter straw.Sharps container Surgical tape Alcohol hand rub/gelAntibiotics/Infusion/additives as prescribed Plastic apron
NB 5ML HEPARINISED SALINE 10 UNITS/MLWITH OPEN ENDED CATHETER
10 ml syringes should always be used. Smaller syringe sizes may damage the
catheter (Hadaway 1998)
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust
policy for the administration of medications. Medication reconstitution should be performed in a clean clinical environment. This
may be performed in an area designated for drug preparation or next to the patient as part of this procedure.
Before the procedure begins make sure that your hands are washed and dried thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times.
Ensures patient compliance and reduce anxiety
Reduce the risk of infection and contamination
Maintain asepsis.
13
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all
packaging is intact and in date. Take equipment/ trolley to the patient Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g.
exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble- shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using
a non touch technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline and
place near to but not on the sterile field. Ensure easy access to the needle free system. Decontaminate hands Put on sterile gloves. Connect needle or filter straw to the syringe. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe and place on sterile field. Place sterile towel as near as possible to the catheter. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Attach syringe with 0.9% sodium chloride for injection, aspirate enough blood to colour 0.9% Sodium Chloride solution then inject the flush using a push pause action clamping as the last ml of the solution is instilled into the catheter. Remove the syringe and discard.
If unable to aspirate blood from the line continue to administer prescribed medication
To check catheter patency and to remove residual solution from catheter. The RCN Standards for infusion Therapy state, “the nurse should aspirate the catheter and check for blood return to confirm patency prior to the administration of medications and/or solutions (INS 2000). On no account
14
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
unless this is a vesicant drug/infusion, in this case refer to algorithm on persistant withdrawal occlusion.
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can easily damage the catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide or contact the hospital team who placed the catheter for advice.
Administer IV antibiotics/infusion/additives as prescribed following trust policy. Flush catheter again with 10ml 0.9% Normal Saline using a push/pause action. Remove the syringe and discard. If open ended skin tunnelled catheter and this is the final dose of treatment for the day,
repeat this procedure using 5ml Heparin 10units/ml in 0.9% sodium chloride clamping as the last ml of solution is instilled into the catheter to maintain catheter patency.
Remove the syringe and discard Clean the needle free connector again with a sani cloth, then wrap the end of the
line in sterile gauze (gauze cot). Tape this to the patients’ chest. Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves and apron. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the
trolley that has been used during the procedure with multi-surface detergent wipes. Wash hands Document care in patient’s records.
should a vesicant drug or vesicant infusion be administered through a vascular access device where difficulty is experienced in withdrawing blood (Masoorli 2003).
Creates turbulence in catheter, preventing clotting in the catheter.
Maintains positive pressure and prevents backflow of blood into the catheter.
the works herein in accordance with the Data Protection Act 1988.Policy review date 01/09/16
15
Algorithm persistent withdrawal occlusion (PWO)i.e. fluids can be infused freely by gravity but blood cannot be withdrawn from the device
Adapted from Standards for Infusion Therapy RCN
(2010)
Blood return is absent
Check equipment,
Position, clamps, kinking. etc
Blood return
obtained - use central venous
catheter as usual
F
lush central venous
catheter with 0.9% Sodium chloride in 10ml syringe using a brisk “push pause” technique. Check for
No
No
Proceed if happy to do
as long as there are no other complications
or pain
Blood return is still absent
Ask patient to cough, deep Breathe, change position, stand up or lie with foot of
the bed tipped up.Ascertain possible cause of
PWO
Blood return is still absent
the works herein in accordance with the Data Protection Act 1988.Policy review date 01/09/16
16SECONDARY CARE
ONLYThe following steps should
initially be done on admission or prior to drug
administration and documented in nursing
care-plan so that all staff are aware that patency has
been verifiedStep 1
Administer a 250ml normal saline “challenge” (unless
serum sodium≤ 120 mmol/l) via an infusion p
ump over 15 minutes to test for patency – the infusion will probably not resolve the lack of blood return (unless the patient has a high sodium or
fluid restricted go to step 2)If there have been no problems, therapy can be administered as normal.
If the patient experiences ANY discomfort or there is any unexplained problems then stop and seek medical advice. It may be necessary to verify tip location by chest X Ray.
ORStep 2 Instill Urokinase 12,500iu in 2 mls and leave for minimum of 2 hours.
After this time withdraw the urokinase and assess the catheter again.Repeat as necessary. If blood return is still absent, it may be
necessary to verify tip location by chest X Ray.The CINs group hereby assert their moral rights to
Yes
Yes
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
171. Department of Health (DOH) (2001) Guidelines for preventing infection associated with the insertion and maintenance of
central venous catheters, Journal of Hospital Infection, 47 Supplement S47 – S67
2. Department of Health (DOH 2003). Winning Ways: Working together to reduce health care associated infection in England
3. Department of Health (DOH 2005). Saving Lives: A delivery programme to reduce health care associated infection including MRSA
4. Goodwin M, Carlson I (1993) The peripherally inserted catheter: a retrospective look at 3 years of insertions, Journal of Intravenous Nursing, 16 (2) 92-103
5. Hadaway L (1998) Catheter connection, Journal of Vascular access devices 3 (3), 40.
6. INS (2000) Infusion Nursing Standards of Practice, Journal of Intravenous Nursing 23 (6S) supplement
7. Treston-Aurand J et al (1997) Impact of dressing materials on central venous catheter infection rates. Journal of Intravenous Nursing 20(4):201-206.
8. Wille JC (1993) A comparison of two transparent film-type dressings in central venous therapy. Journal of Hospital Infection 23(2):113- 121.
9. Pratt RJ et al (2006) National Evidence-Based Guidelines for Preventing Healthcare-Associated Infections in NHS Hospitals in England (epic 2). Thames Valley University, London.
10.RCN (2010) Standards for infusion therapy. Cambridge, MA: INS and Becton Dickinson (III). In RCN Standards for Infusion (2005)
11.Masoorli S (2003) Extravasation injuries associated with the use of central venous access devices. Journal of vascular access devices. 21-23 Spring
18
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Care and Maintenance of a non tunnelled Central Venous Catheter (CVC1) All lumens on a non-tunnelled access device should be flushed using an aseptic technique.
EXIT DRESSING CHANGE (Weekly)
Action RationaleEquipment required
Dressing Pack containing sterile towel and Gloves Surgical tapeChlorhexidine 2% impregnated applicator (SEPP) Chlorhexidine 2% wipe (sani cloth)Semi-Permeable transparent IV dressing Alcohol hand rub or gel
Care of Exit site Dressing changes should be performed on a weekly basis or when dressing is dirty or loose.
Explain the procedure to the patient. Ensure that valid consent is gained. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times.
To prevent/reduce patient anxiety.
To prevent infection
Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packing is
intact and in date Take equipment/trolley to patient.
To prevent infection and catheter contamination.
Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g. exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please
19
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide.
Decontaminate hands Open sterile pack and use a non-touch technique to place inner pack onto clean working
area. Open out sterile pack to create an aseptic field. Open remaining equipment using a
non touch technique, ensuring no contamination of aseptic field.
Loosen exit site dressing. To loosen dressing lift lower-end and gently ease the dressing off, from the skin.
To allow for a sterile environment for accessing intravenous catheter,and to reduce incidence of infection.
To prevent accidental removal of the catheter and friction or trauma to skin surface.
Aseptically remove the dressing Decontaminate hands Put on sterile gloves Place sterile towel as near as possible to the catheter exit site. Clean around the catheter and exit site Chlorhexidine 2% impregnated applicator
(SEPP). The solution should be applied with friction, but should not be too vigorous or the skin's natural defence may be destroyed.
Using a Chlorhexidine 2% wipe, carefully clean the catheter from the exit site to the part of the catheter that will be covered by the sterile dressing.
Allow to dry. Apply new securing device i.e. Skin closure strips or skin fixation device (if required) Apply new dressing to exit site without touching the adhesive site. Remove the dressing towel Remove gloves. Clear away equipment disposing of waste as per organisational policy. Wipe down the
trolley that has been used during the procedure with multi-surface detergent wipes. Wash hands. Document care on patient’s records.
Chlorhexidine based solutions are recommended (in alcohol) as per policy (DOH 2001).
Alcohol Chlorhexidine combines the benefits of rapid action and excellent residual activity (DOH 2001).
Semi-permeable transparent IV dressings are well tolerated by patients (Campbell et al 1999, Treston-Aurand et al 1997, Wille 1993) and are easy to apply and remove (Wille 1997).
20
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Central Non-Tunnelled Catheters - Saline Flush and Hepsal Lock (CVC2)If each lumen of a triple or quadruple lumen catheter is being used more than once a day there is no need for a Hepsal flush
Action RationaleEquipment Required Dressing Pack containing sterile towel and gloves 10ml syringes x 1Chlorhexidine 2% impregnated wipes x 310ml 0.9% Sodium Chloride for injection(Saline) prefilled syringes or a 10ml ampoule of 0.9% Normal Saline5ml Heparin 10units/ml in 0.9% Sodium Chloride 1 x blue needle/filter strawSharps container Surgical tape Alcohol hand rub/gel Plastic apronNeedle free I/V access connector change as per manufacturer’s guidelines see NSF1 Cins guideline
NB 5ML HEPARINISED SALINE 10 UNITS/ML WITH OPEN ENDED CATHETER
10ml syringes should always be used; smaller syringe sizes may damage the catheter (Hadaway 1998).
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust policy
for the administration of medications. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times. Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packaging is
Reduce anxiety Patient complianceTo ensure that the procedure can be carried out safely
Reduce risk of infection. To avoid contamination.
21
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
intact and in date. Take equipment /trolley to patient Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g.
exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using a
non touch technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline and
place near to but not on the sterile field. Decontaminate hands. Put on sterile gloves. Connect needle/ filter straw to the syringe. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe (if required) and place on sterile field. Place sterile towel as near as possible to the catheter. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Attach syringe with 0.9% Sodium Chloride (saline) flush and inject the flush using a push/pause action, clamping as the last ml of solution is instilled into the catheter.
Remove the syringe and discard. Repeat flush now using Heparinised saline if required. NEVER FORCE THE SOLUTION INTO THE CATHETER, this can damage the catheter.
The solution should flow easily. If resistance felt, refer to trouble shooting guide or contact the hospital team who placed the catheter for advice.
Clean the needle free connector again with a sanicloth, then wrap the end of the line in sterile gauze (gauze cot). Tape this to patient’s skin.
To maintain an aseptic field
Chlorhexidine based solutions are recommended (in alcohol) as per policy (DOH 2001).There is no requirement to routinely withdraw blood and discard it prior to flushing (except prior to blood sampling although the first sample can be used for blood cultures (RCN 2005).There is an increased risk of infection and occlusion when withdrawing blood via a central venous catheter (RCN 2005), therefore for routine flushing of a line
22
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down
the trolley that has been used during the procedure with multi-surface detergent wipes.
Decontaminate hands. Document care in patient’s records.
withdrawal of blood is not required. The pulsated flush creates turbulence within the catheter lumen, removing debris from the internal catheter wall (Goodwin & Carlson 1993, Todd 1998).Positive pressure within the lumen of the catheter should be maintained to prevent reflux of blood (INS 2000).10ml syringes should always be used; smaller syringe sizes may damage the catheter (Hadaway 1998).
23
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Central Non-Tunnelled Catheters – Blood Sampling (CVC3) If a triple or quadruple lumen catheter is being used more than once a day there is no need for a Hepsal flushFor multi-lumen non-tunnelled catheters ideally one lumen should be used for blood sampling.
Action RationaleEquipment Required Dressing Pack containing sterile towel and gloves 10ml syringes x 32% Chlorhexidine impregnated wipes x 210ml 0.9% Sodium Chloride for injection, prefilled syringe (or 10ml ampoule of 0.9% Normal Saline)5ml Heparin 10units/ml in 0.9% Normal Saline One blue needle/filter straw. Sharps container Surgical tapeAlcohol hand rub/gel ApronNeedle free I/V access connector change as per manufacturer’s guidelines see NSF1 Cins guideline
NB 5ML HEPARINISED SALINE 10 UNITS/MLWITH OPEN ENDED CATHETER
10 ml syringes should always be used. Smaller syringe sizes may damage the catheter (Hadaway 1998)
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust policy
for the administration of medications. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times. Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packaging is
intact and in date. Take equipment/ trolley to patient Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g.
Reduce anxiety Patient compliance Maintain safety.
Reduce risk of infection. To avoid contamination.
To ensure that the procedure can be carried out safely
24
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using a
non touch technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline (if required)
and place near to but not on the sterile field. Ensure easy access to the needle free system. Decontaminate hands Put on sterile gloves. Connect needle/filter straw to the syringe. Place sterile towel as near as possible to the catheter. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe (if required) and place on sterile field. Place sterile towel as near as possible to the catheter. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Attach empty 10ml syringe into needle free system and aspirate at least 3 to 5ml of blood from the catheter. If unable to do so attach the syringe containing the saline solution to the needle free system gently flush with 1-2mls 0.9% Sodium Chloride (do not use force) then aspirate blood from catheter. Discard blood aspirated as per policy. Note if taking blood samples from a parenteral nutrition line or for INR sample at least10-20mls of blood should be taken and disguarded before taking the sample (check local policy).
Attach an empty 10ml syringe and withdraw amount of blood required for analysis. Attach syringe with 0.9% Sodium Chloride (saline) flush and inject the flush using a
To maintain an aseptic field
Chlorhexidine based solutions are recommended (in alcohol) as per policy (DOH 2001).
Check catheter patency. Remove any residual solution from catheter.
The pulsated flush creates turbulence
25
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
push/pause action, clamping as the last ml of solution is instilled into the catheter. Remove the syringe and discard. Repeat flush now using Heparinised saline if required. NEVER FORCE THE SOLUTION INTO THE CATHETER, this can damage the catheter.
The solution should flow easily. If resistance felt, refer to trouble shooting guide or contact IV access team.
Clean the needle free connector again with a sani cloth, then wrap the end of the line in sterile gauze (gauze cot). Tape this to patients’ skin.
Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down
the trolley that has been used during the procedure with multi-surface detergent wipes.
Decontaminate hands. Document care in patient’s records.
within the catheter lumen, removing debris from the internal catheter wall (Goodwin & Carlson 1993, Todd 1998). Positive pressure within the lumen of the catheter should be maintained to prevent reflux of blood (INS 2000).
26
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Central Venous Non-Tunnelled Catheters – Administration of antibiotics/additives/infusions (CVC4)
Administer drugs or IV therapy as prescribed using correct diluent and rate of infusion. Always use 10ml syringe, never use force to flush the catheter. If a triple or quadruple lumen catheter is being used more than once a day there is no need for a Hepsal flush
Action RationaleEquipment Required Dressing pack containing sterile towel and gloves 2% Chlorhexidine impregnated wipes x 210ml syringes x 4 (this will vary depending on amount of medication being administered).2 x 10ml 0.9% Sodium Chloride (saline) prefilled syringes (or ampoules) 5ml Heparin 10units/ml in 0.9% Sodium ChlorideTwo needles/ filter straws (this will vary depending on medication being administered).Sharps container Surgical tape Alcohol hand rub/gel Plastic apronAntibiotics/additive/infusion as prescribed
NB 5ML HEPARINISED SALINE 10 UNITS/MLWITH OPEN ENDED CATHETER
10 ml syringes should always be used. Smaller syringe sizes may damage the
catheter (Hadaway 1998)
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust policy
for the administration of medications. Medication reconstitution should be performed in a clean clinical environment. This may
be performed in an area designated for drug preparation or at the patient’s bedside as part of this procedure.
Before the procedure begins make sure that your hands are washed and dried thoroughly and that they continue to be decontaminated during the procedure. A plastic
Reduce the risk of infection and contamination.
Ensures patient compliance and reduce anxiety
27
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
apron should be worn. Maintain aseptic technique at all times Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packaging
is intact and in date. Take equipment/ trolley to patient Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g.
exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using a non
touch technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline (if required)
and place near to but not on the sterile field. Remove dust cap from antibiotic vial/vials and place near to but not on sterile the field. Ensure easy access to the needle free system. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe (if required) and place on sterile field. Reconstitute antibiotics in accordance with manufacturer’s guidelines (as appropriate)
Decontaminate hands Put on sterile gloves. Connect needle or filter straw to the syringe. Place sterile towel as near as possible to the catheter. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Maintain asepsis.
28
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Attach syringe with 0.9% sodium chloride for injection, aspirate enough blood to colour 0.9% Sodium Chloride solution then inject the flush using a push pause action clamping as the last ml of the solution is instilled into the catheter. Remove the syringe and discard.
If unable to aspirate blood from the line continue to administer prescribed medication unless this is a vesicant drug/infusion, in this case refer to algorithm on persistant withdrawal occlusion.
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can easily damage the catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide or contact the hospital team who placed the catheter for advice
Administer IV antibiotics/infusion/additives as prescribed following trust policy. Flush catheter again with 10ml 0.9% Normal Saline using a push/pause action. Remove the syringe and discard. If this is the final dose of treatment for the day, repeat this procedure using 5ml Heparin
10units/ml in 0.9% sodium chloride clamping as the last ml of solution is instilled into the catheter to maintain catheter patency.
Remove the syringe and discard Clean the needle free connector again with a sani cloth, then wrap the end of the line
in sterile gauze (gauze cot). Tape this to the patient’s chest. Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves and apron. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the
trolley that has been used during the procedure with multi-surface detergent wipes. Wash hands Document care in patient’s records.
To check catheter patency and to remove residual solution from catheter.The RCN Standards for infusion Therapy state, “the nurse should aspirate the catheter and check for blood return to confirm patency prior to the administration of medications and/or solutions (INS 2000). On no account should a vesicant drug or vesicant infusion be administered through a vascular access device where difficulty is experienced in withdrawing blood (Masoorli 2003).
Creates turbulence in catheter, preventing clotting in the catheter.
Maintains positive pressure and prevents backflow of blood into the catheter.
the works herein in accordance with the Data Protection Act 1988.Policy review date 01/09/16
29
Algorithm persistent withdrawal occlusion (PWO)i.e. fluids can be infused freely by gravity but blood cannot be withdrawn from the device
Adapted from Standards for Infusion Therapy RCN
(2010)
Blood return is absent
Check equipment,
Position, clamps, kinking. etc
Blood return
obtained - use central venous
catheter as usual
F
lush central venous
catheter with 0.9% Sodium chloride in 10ml syringe using a brisk “push pause” technique. Check for
No
No
Proceed if happy to do
as long as there are no other complications
or pain
Blood return is still absent
Ask patient to cough, deep breathe, change position, stand up or lie with foot of
the bed tipped up.Ascertain possible cause of
PWO
Blood return is still absent
the works herein in accordance with the Data Protection Act 1988.Policy review date 01/09/16
30SECONDARY CARE
ONLYThe following steps should
initially be done on admission or prior to drug
administration and documented in nursing
care-plan so that all staff are aware that patency has
been verifiedStep 1
Administer a 250ml normal saline “challenge” (unless
serum sodium≤ 120 mmol/l) via an infusion p
ump over 15 minutes to test for patency – the infusion will probably not resolve the lack of blood return (unless the patient has a high sodium or
fluid restricted go to step 2)If there have been no problems, therapy can be administered as normal.
If the patient experiences ANY discomfort or there is any unexplained problems then stop and seek medical advice. It may be necessary to verify tip location by chest X Ray.
ORStep 2 Instill Urokinase 12,500iu in 2 mls and leave for minimum of 2 hours.
After this time withdraw the urokinase and assess the catheter again.Repeat as necessary. If blood return is still absent, it may
be necessary to verify tip location by chest X Ray.The CINs group hereby assert their moral rights to
Yes
Yes
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
3112.Department of Health (DOH) (2001) Guidelines for preventing infection associated with the insertion and maintenance of
central venous catheters, Journal of Hospital Infection, 47 Supplement S47 – S67
13.Department of Health (DOH 2003). Winning Ways: Working together to reduce health care associated infection in England
14.Department of Health (DOH 2005). Saving Lives: A delivery programme to reduce health care associated infection including MRSA
15.Goodwin M, Carlson I (1993) The peripherally inserted catheter: a retrospective look at 3 years of insertions, Journal of Intravenous Nursing, 16 (2) 92-103
16.Hadaway L (1998) Catheter connection, Journal of Vascular access devices 3 (3), 40.
17. INS (2000) Infusion Nursing Standards of Practice, Journal of Intravenous Nursing 23 (6S) supplement
18.Treston-Aurand J et al (1997) Impact of dressing materials on central venous catheter infection rates. Journal of Intravenous Nursing 20(4):201-206.
19.Wille JC (1993) A comparison of two transparent film-type dressings in central venous therapy. Journal of Hospital Infection 23(2):113- 121.
20.Pratt RJ et al (2006) National Evidence-Based Guidelines for Preventing Healthcare-Associated Infections in NHS Hospitals in England (epic 2). Thames Valley University, London.
21. INS (2000) Standards for infusion therapy. Cambridge, MA: INS and Becton Dickinson (III). In RCN Standards for Infusion (2005)
22.Masoorli S (2003) Extravasation injuries associated with the use of central venous access devices. Journal of vascular access devices. 21-23 Spring
32
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Care and Maintenance of a Peripheral Inserted Central Catheter (PICC). (PL1)
EXIT DRESSING CHANGE (Weekly)
A
ction RationaleEquipment r e quired Dressing Pack containing sterile towel and Gloves Surgical tape
2% Chlorhexidine impregnated applicator (SEPP) Chlorhexidine impregnated wipe (sani cloth) Semi-Permeable transparent IV dressingAlcohol hand rub or gelSkin fixation device (e.g. stat-lock or grip lock) Plastic apron
Care of E x it site Dressing changes should be performed on a weekly basis or when dressing is dirty or loose.
Explain the procedure to the patient. Ensure that valid consent is gained. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times
To prevent infection
Exit site dressings are important in preventing trauma and the extrinsic contamination of the site of entry (Jones 2004).
Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packaging is
intact and in date. Take equipment/ trolley to patient. Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g.
exudate from exit site. Check observation and VIAD chart for any indications of infection
To prevent/reduce patient anxiety Maintain safetyTo minimise the risk of infection and catheter contamination.
33
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide.
Decontaminate hands Open sterile pack and use a non-touch technique to place inner pack onto clean
working area. Open out sterile pack to create an aseptic field. Open remaining equipment using a non
touch technique, ensuring no contamination of aseptic field.
Loosen exit site dressing. To loosen dressing lift lower-end and gently ease the dressing off, from the skin. Dressing should be removed from hand to elbow to prevent accidental catheter removal. Be aware that the fixation device may also come off with the dressing.
To allow for a sterile environment for accessing intravenous device.
Chlorhexidine based solutions are recommended (in alcohol) dependent on the availability and catheter manufacturers. Recommendations (DOH 2001).
To prevent accidental removal of the catheter and friction or trauma to the skin surface
Aseptically remove the dressing. Decontaminate hands Put on sterile gloves Place sterile towel as near as possible to the PICC catheter. Clean around the catheter and exit site with Chlorhexidine 2% impregnated applicator
(SEPP). The solution should be applied with friction but should not be too vigorous or the
skin's natural defence may be destroyed. Using a Chlorhexidine 2% wipe (sani cloth), carefully clean the catheter from the exit
site to the part of the catheter that will be covered by the sterile dressing. Allow to dry. Apply new securing device i.e. Skin closure strips or skin fixation device. Apply new dressing to exit site. Remove the dressing towel Remove gloves and wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the
Alcoholic Chlorhexidine combines the benefits of rapid action and excellent residual activity (DOH 2001)
Semi-permeable transparent IV dressings are well tolerated by patients (Campbell et al 1999, Treston-Aurand et al 1997, Wille 1993) and are easy to apply and remove (Wille 1997).
34
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
trolley that has been used during the procedure with multi-surface detergent wipes. Wash hands. Document care on patient’s records.
35
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Peripherally Inserted Central Catheter – 0.9% Sodium Chloride for injection and Heparin 10 units/ml in 0.9% Sodium Chloride for injection Lock (PL2) for weekly maintenance Flush
Action RationaleEquipment Required Dressing Pack containing sterile towel and gloves 10ml syringes x 1Chlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated wipe 10ml 0.9% Sodium chloride for injection prefilled syringeOne blue needle/filter straw. Sharps container Surgical tapeAlcohol hand rub Plastic apronNeedle free I/V access connector change as per manufacturer’s guidelines see NSF1 Cins guideline
NB 5ML HEPARIN 10 UNITS/ML in 0.9% SODIUM CHLORIDE WITH OPEN ENDED CATHETER
10ml syringes should always be used, smaller syringe sizes may damage the catheter (Hadaway 1998)
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust
policy for the administration of medications. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times. Ensure working area is clean. Ensure all equipment is gathered before commencing the procedure and all packaging
is intact and in date. Take equipment/trolley to patient Inspect the catheter exit site for signs of skin discolouration or signs of infection, e.g.
exudate from exit site. Check observation and VIAD chart for any indications of
Reduce anxiety and improve patient compliance
Maintain asepsis.
Reduce risk of infection. To avoid contamination and to reduce risk of infection
36
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble- shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using
a non touch technique, ensuring no contamination of aseptic field. Ensure easy access to the needle free system. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline (if
required) and place near to but not on the sterile field. Decontaminate hands. Put on sterile gloves. Connect needle/ filter straw to the syringe. Place sterile towel as near as possible to the catheter Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe (if required) and place on sterile field. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe over a period of 30 seconds. Allow to dry.
Attach syringe with 0.9% Sodium Chloride flush and inject the flush using a push/pause action, clamping as the last ml of solution is instilled into the catheter.
Remove the syringe and discard. If open ended PICC repeat this procedure using syringe containing 5ml Heparin 10units/ml in 0.9% Sodium Chloride.
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can damage the catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide or contact IV access team.
Clean the needle free connector again with a sani cloth, then wrap the end of the line in sterile gauze (gauze cot). Tape this to the patient’s arm.
Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves. Wash hands.
Chlorhexidine based solutions are recommended (in alcohol) as per policy (DOH 2001).
There is no requirement to routinely withdraw blood and discard it prior to flushing (except prior to blood sampling although the first sample can be used for blood cultures (RCN 2005).
There is an increased risk of infection and occlusion when withdrawing blood via a central venous catheter (RCN 2005), therefore for routine flushing of
37
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Clear away equipment disposing of waste as per organisational policy. Wipe down the trolley that has been used during the procedure with multi-surface detergent wipes
Decontaminate hands Document care in patient’s records.
a line withdrawal of blood is not required.
The pulsated flush creates turbulence within the catheter lumen, removing debris from the internal catheter wall (Goodwin & Carlson 1993, Todd 1998).Positive pressure within the lumen of the catheter should be maintained to prevent reflux of blood (INS 2000).
38
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Peripherally Inserted Central Catheter – Blood Sampling (PL3)
A
ction RationaleEquipment Required Dressing Pack containing sterile towel and gloves 10ml syringes x 4Chlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated wipe (Sani Cloth) x 210ml 0.9% Sodium Chloride for injection prefilled syringe (or ampoule) One green needle/filter straw. Sharps containerSurgical tape Alcohol hand rubNeedle free I/V access connector change as per manufacturer’s guidelines see NSF1 CINs guideline
NB 5ML HEPARINISED SALINE 10 UNITS/MLWITH OPEN ENDED CATHETER
10 ml syringes should always be used. Smaller syringe sizes may damage the catheter (Hadaway 1998)
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust
policy for the administration of medications. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times. Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packaging
is intact and in date. Take equipment/ trolley to patient. Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g.
exudate from exit site. Check observation and VIAD chart for any indications of
Reduce anxiety and improve patient compliance
Maintain asepsis.
Reduce risk of infection. To avoid contamination and to reduce risk of infection
39
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble- shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using
a non touch technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline (if
required) and place near to but not on the sterile field. Ensure easy access to the needle free system. Decontaminate hands Put on sterile gloves. Connect needle/filter straw to the syringe. Place sterile towel as near as possible to the catheter. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe (if required) and place on sterile field. Place sterile towel as near as possible to the catheter. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Attach empty 10ml syringe into needle free system and aspirate at least 3 to 5ml of blood from the catheter. If unable to do so attach the syringe containing the saline solution to the needle free system gently flush with 1-2mls 0.9% Sodium Chloride (do not use force) then aspirate blood from catheter. Discard blood aspirated as per policy. Note if taking blood samples from a parenteral nutrition line or for INR sample at least 10-20mls of blood should be taken and disguarded before taking the sample (check local policy).
Attach an empty 10ml syringe and withdraw amount of blood required for analysis. Attach syringe with 0.9% Sodium Chloride (saline) flush and inject the flush using
a push/pause action, clamping as the last ml of solution is instilled into the catheter.
Chlorhexidine based solutions are recommended (in alcohol) as per policy (DOH 2001)
The pulsated flush creates turbulence within the catheter lumen, removing debris from the internal catheter wall (Goodwin & Carlson 1993, Todd 1998).
Positive pressure within the lumen of the catheter should be maintained to prevent reflux of blood (INS 2000).
40
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Remove the syringe and discard. If open ended PICC, repeat this procedure using 5ml Heparinised saline lock.
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can damage the catheter. The solution should flow easily. If resistance felt, refer to trouble shooting guide or contact IV access team.
Clean the needle free connector again with a sani cloth, then wrap the end of the line in sterile gauze (gauze cot). Tape this to patients’ skin.
Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down
the trolley that has been used during the procedure with multi-surface detergent wipes.
Decontaminate hands. Document care in patient’s records.
41
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Peripherally Inserted Central Catheter – Administration of antibiotics/additives/infusion (PL4)Administer drugs or IV therapy as prescribed using correct diluent and rate of infusion. Always use 10ml syringe, never use force to flush the catheter.
Action RationaleEquipment Required Dressing pack containing sterile towel and gloves GlovesChlorhexidine impregnated wipes x 2 (sani cloth)10ml syringes x 3 (may vary depending on amount of medication being administered)2 x 10ml 0.9% Sodium chloride (saline) prefilled syringes (or ampoules)One blue needle/ filter straw (may vary depending on amount of medication being administered)Sharps container Surgical tape Alcohol hand rub Plastic apronAntibiotics/additives/infusion as prescribed
NB 5ML HEPARINISED SALINE 10UNITS/ML FOR OPEN ENDED CATHETER
10 ml syringes should always be used. Smaller syringe sizes may damage the
catheter (Hadaway 1998)
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust
policy for the administration of medications. Medication reconstitution should be performed in a clean clinical environment. This
may be performed in an area designated for drug preparation or at the patient’s bedside as part of this procedure.
Before the procedure begins make sure that your hands are washed and dried thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times
Ensures patient compliance and reduces anxiety
To minimise risks of infection and contamination.
Maintain asepsis.
42
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all
packaging is intact and in date. Take equipment trolley to patient. Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g.
exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble- shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using
a non touch technique, ensuring no contamination of aseptic field. Ensure easy access to the needle free system. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline (if
required) and place near to but not on the sterile field Remove dust cap from antibiotic vial/vials and place near to but not on sterile the field. Decontaminate hands Put on sterile gloves. Connect needle or filter straw to the syringe. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe (if required) and place on sterile field. Reconstitute antibiotics in accordance with manufacturer’s guidelines (as appropriate) Place sterile towel as near as possible to the catheter. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Flush catheter with 10ml 0.9% Normal Saline using a push/pause action. Remove the syringe and discard.
Chlorhexidine based solutions are recommended (in alcohol) dependent on the availability and catheter manufacturers recommendations (DOH 2001).
To check catheter patency and to remove residual solution from catheter.
The pulsated flush creates turbulence
43
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can easily damage the catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide or contact IV access team.
Administer IV antibiotics/infusion/additives as prescribed following trust policy. Flush catheter again with 10ml 0.9% Normal Saline using a push/pause action. Remove the syringe and discard. If open ended PICC and this is the final dose of treatment for the day, repeat this
procedure using 5ml Heparin 10units/ml in 0.9% sodium chloride clamping as the last ml of solution is instilled into the catheter to maintain catheter patency.
Remove the syringe and discard Clean the needle free connector again with a sani cloth, then wrap the end of the
line in sterile gauze (gauze cot). Tape this to the patients’ chest. Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves and apron. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the
trolley that has been used during the procedure with multi-surface detergent wipes. Wash hands Document care in patient’s records.
within the catheter lumen, removing debris from the internal catheter wall (Goodwin & Carlson 1993, Todd 1998).Positive pressure within the lumen of the catheter should be maintained to prevent reflux of blood (INS 2000).
42
Policy review date 01/09/16
Algorithm persistent withdrawal occlusion (PWO)i.e. fluids can be infused freely by gravity but blood cannot be withdrawn from the device
Adapted from Standards for
Infusion
The C
Blood return is absent
Check equipment,
Position, clamps, kinking. etc
Blood return
obtained - use central venous
catheter as usual
F
lush central venous
catheter with 0.9% Sodium chloride in 10ml syringe using a brisk “push pause” technique. Check for
No
No
Proceed if happy to do
as long as there are no other complications
or pain
Blood return is still absent
Ask patient to cough, deep breathe, change position, stand up or lie with foot of
the bed tipped up.Ascertain possible cause of
PWO
43
Policy review date 01/09/16
INs group hereby assert their moral rights to
SECONDARY CARE ONLYThe following steps should initially be done on admission or prior to
drug administration and documented in nursing care-plan so that all staff are aware that patency
has been verifiedStep 1
Administer a 250ml normal saline “challenge” (unless serum sodium
– the infusion will probably not resolve the lack of blood return (unless the patient has a high sodium or fluid restricted go to step 2)
If there have been no problems, therapy can be administered as normal.If the patient experiences ANY discomfort or there is any
unexplained problems then stop and seek medical advice. It may be necessary to verify tip location by chest X Ray.
ORStep 2 Instill Urokinase 12,500iu in 2 mls and leave for minimum of 2 hours.
After this time withdraw the urokinase and assess the catheter again.Repeat as necessary. If blood return is still absent, it may be
necessary to verify tip location by chest X Ray.Therapy RCN (2010) the works herein in accordance with the Data Protection Act 1988.
Yes
Blood return is still absent
Yes
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
44
References
1. Department of Health (DOH) (2001) Guidelines for preventing infection associated with the insertion and maintenance of central venous catheters, Journal of Hospital Infection, 47 Supplement S47 – S67
2. Department of Health (DOH 2003). Winning Ways: Working together to reduce health care associated infection in England
3. Department of Health (DOH 2005). Saving Lives: A delivery programme to reduce health care associated infection including MRSA
4. Goodwin M, Carlson I (1993) The peripherally inserted catheter: a retrospective look at 3 years of insertions, Journal of Intravenous Nursing, 16 (2) 92-103
5. Hadaway L (1998) Catheter connection, Journal of Vascular access devices 3 (3), 40.
6. Infection Control Nurses Association (2001) Guidelines for Preventing Intravascular Catheter-related Infection.
7. INS (2000) Infusion Nursing Standards of Practice, Journal of Intravenous Nursing 23 (6S) supplement
8. Todd J (1998) Peripherally inserted central catheters. Professional Nurse 13(5) 297-302
9. Jones A (2004) Dressings for the Management of Catheter Sites – A review. JAVA, Vol. 9 No 1, 1-8.
10.Campbell H, Carrington M (1999) Peripheral IV cannula dressings: advantages and disadvantages. British Journal of Nursing, 8(21):1420-1422, 1424-1427
11.Treston-Aurand J et al (1997) Impact of dressing materials on central venous catheter infection rates. Journal of Intravenous Nursing 20(4):201-206.
12.Wille JC (1993) A comparison of two transparent film-type dressings in central venous therapy. Journal of Hospital Infection 23(2):113- 121.
13. INS (2000) Standards for infusion therapy. Cambridge, MA: INS and Becton Dickinson (III) In RCN Standards for Infusion (2005).
45
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
14.Masoorli S (2003) Extravasation injuries associated with the use of central venous access devices. Journal of vascular access devices. 21-23 Spring
45
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Care and Maintenance of a Peripheral Midline Catheter (PM1)
EXIT DRESSING CHANGE (Weekly)
Action RationaleEquipment requiredDressing Pack containing sterile towel and Gloves Surgical tapeChlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated applicator (SEPP)Semi-Permeable transparent IV dressing Alcohol hand rub or gelSkin fixation device (e.g. stat-lock or grip look) Plastic apron.Care of Exit site Dressing changes should be performed on a weekly basis or when dressing is dirty or loose.
Explain the procedure to the patient. Ensure that valid consent is gained. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times.
To prevent infection
Exit site dressings are important in preventing trauma and the extrinsic contamination of the site of entry (Jones 2004).
Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packing is
intact and in date. Take equipment /trolley to patient.
To prevent/reduce patient anxiety Maintain safety and reassure patient.
To prevent infection and catheter contamination.
Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g. exudate from exit site. Check observation and VIAD chart for any indications of infection
46
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
or compl
ications. Ensure the intravenous access device has been comfortable and
pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide.
Decontaminate hands
To allow for a sterile environment for accessing intravenous catheter.
To reduce incidence of infection
To prevent accidental removal of the catheter and friction or trauma to skin surface.
Aseptically remove the dressing. Decontaminate hands Put on sterile gloves Place sterile towel as near as possible to the midline catheter. Clean around the catheter and exit site with Chlorhexidine 2% impregnated
applicator (SEPP). The solution should be applied with friction but should not be too vigorous or the
skin's natural defence may be destroyed. Using a Chlorhexidine 2% wipe (sani cloth), carefully clean the catheter from the
exit site to the part of the catheter that will be covered by the sterile dressing. Allow to dry. Apply new securing device i.e. Skin closure strips or skin fixation device. Apply new dressing to exit site without touching the adhesive site. Remove the dressing towel Remove gloves and wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down
the trolley that has been used during the procedure with multi-surface detergent wipes.
Decontaminate hands.
Chlorhexidine based solutions are recommended (in alcohol) as per policy (DOH 2001)
Alcoholic Chlorhexidine combines the benefits of rapid action and excellent residual activity (DOH 2001)
Semi-permeable transparent IV dressings are well tolerated by patients (Campbell et al 1999, Treston-Aurand et al 1997, Wille 1993) and are easy to apply and remove (Wille 1997).
47
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Peripheral Midline - 0.9% Sodium Chloride and Heparin 10 units/ml in 0.9% Sodium Chloride for injection Lock (PM2) (At least once daily, more frequently if required) It is not always possible to aspirate blood from a peripheral midline, as the lumen of the catheter maybe too small. If using a 2.5fr device blood withdrawal is not always possible.
A
ction RationaleEquipment Required Dressing Pack containing sterile towel and gloves 10ml syringes x 12% Chlorhexidine impregnated wipe x 2 (Sani cloth)10ml 0.9% Sodium Chloride for injection prefilled syringes(or ampoules) 5mls Heparin 10units/ml in Sodium ChlorideOne Blue needle/filter straw. Sharps containerSurgical tape Alcohol hand rub Plastic apronNeedle free I/V access connector change as per manufacturer’s guidelines see NSF1 Cins guideline
N B 5 M L H E P A R INISED S A L I N E 10 UN I T S / M L F OR OP EN E ND ED C A TH E T ER
10 ml syringes should always be used. Smaller syringe sizes may damage the catheter (Hadaway 1998)
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust
policy for the administration of medications. Before the procedure begins make sure that your hands are washed and dried
thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times. Ensure working area is clean. Ensure all equipment is gathered before commencing the procedure and all packaging
is intact and in date.
Reduce anxiety and improve patient compliance
Maintain asepsis.
Reduce risk of infection.
48
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Take equipment/trolley to patient. Inspect the catheter exit site for signs of skin discolouration or signs of infection, e.g.
exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble- shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using
a non touch technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline (if
required) and place near to but not on the sterile field. Ensure easy access to the needle free system. Decontaminate hands. Put on sterile gloves. Connect needle/ filter straw to the syringe. Place sterile towel as near as possible to the catheter Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe (if required) and place on sterile field. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe over a period of 30 seconds. Allow to dry.
Attach syringe with 0.9% Sodium Chloride (saline) flush and inject the flush using a push/pause action, clamping as the last ml of solution is instilled into the catheter. Remove the syringe and discard.
If open ended midline repeat this procedure using syringe containing 5ml Heparin 10units/ml in 0.9% Sodium Chloride.
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can damage the catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide or contact the hospital team who placed the device.
Chlorhexidine based solutions are recommended (in alcohol) dependent on the availability and catheter manufacturers recommendations (DOH 2001).
The pulsated flush creates turbulence within the catheter lumen, removing debris from the internal catheter wall (Goodwin & Carlson 1993, Todd 1998).Positive pressure within the lumen of the catheter should be maintained to
49
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Clean the needle free connector again with a sani cloth, then wrap the end of the line in sterile gauze (gauze cot). Tape this to the patients’ arm.
Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the
trolley that has been used during the procedure with multi-surface detergent wipes Decontaminate hands Document care in patient’s records.
prevent reflux of blood (INS 2000).
50
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Peripheral Midline – Administration of antibiotics/infusion/additives (PM3) Administer drugs or IV therapy as prescribed using correct diluent and rate of infusion.
A
ction RationaleEquipment Required Dressing pack containing sterile towel and gloves Chlorhexidine impregnated wipes x 210ml syringes x 3 (may vary depending on amount of medication being administered) 2 x 10ml 0.9% Sodium chloride (saline) prefilled syringes (or ampoules)5ml Heparin 10units/ml in 0.9%Sodium ChlorideOne green needle/ filter straw (may vary depending on amount of medication being administered)Sharps container Surgical tape Alcohol hand rub Plastic apronAntibiotics/additives/infusion as prescribed
NB 5ML HEPARINISED SALINE 10UNITS/ML FOR OPEN ENDED CATHETER
10 ml syringes should always be used. Smaller syringe sizes may damage the catheter (Hadaway
1998)
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust policy
for the administration of medications. Medication reconstitution should be performed in a clean clinical environment. This may
be performed in an area designated for drug preparation or at the patient’s bedside as part of this procedure.
Before the procedure begins make sure that your hands are washed and dried thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packaging is
Reduce the risk of infection and contamination
Ensures patient compliance and reduces anxiety
Maintain asepsis.
Reduce the risk of infection and contamination.
51
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
intact and in date. Take equipment trolley to patient. Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g.
exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using a
non touch technique, ensuring no contamination of aseptic field. Place sterile towel as near as possible to the catheter. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline (if required)
and place near to but not on the sterile field Remove dust cap from antibiotic vial/vials and place near to but not on sterile the field. Decontaminate hands Put on sterile gloves. Connect needle or filter straw to the syringe. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up
5ml Heparinised Saline into 10ml syringe (if required) and place on sterile field. Reconstitute antibiotics in accordance with manufacturer’s guidelines (as appropriate) Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Attach syringe with 0.9% sodium chloride for injection, inject the flush using a push pause action clamping as the last ml of the solution is instilled into the catheter. If using a 2.5 fr midline blood return is not possible. Remove the syringe and discard.
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can easily damage the catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide
To avoid contamination
Chlorhexidine based solutions are recommended (in alcohol) dependent on the availability and catheter manufacturers recommendations (DOH 2001).
The pulsated flush creates
52
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
or contact IV access team. Administer IV antibiotics/infusion/additives as prescribed following trust policy. Flush catheter again with 10ml 0.9% Normal Saline using a push/pause action. Remove the syringe and discard. If open ended midline and this is the final dose of treatment for the day, repeat this
procedure using 5ml Heparin 10units/ml in 0.9% sodium chloride clamping as the last ml of solution is instilled into the catheter to maintain catheter patency.
Remove the syringe and discard Clean the needle free connector again with a sani cloth, then wrap the end of the line
in sterile gauze (gauze cot). Tape this to the patients’ chest. Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves and apron. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the
trolley that has been used during the procedure with multi-surface detergent wipes. Decontaminate hands. Document care in patient’s records.
turbulence in catheter, preventing clotting in the catheter.
Maintains positive pressure and prevents backflow of blood into the catheter.
53
References
1. Department of Health (DOH) (2001) Guidelines for preventing infection associated with the insertion and maintenance of central venous catheters, Journal of Hospital Infection, 47 Supplement S47 – S67
2. Department of Health (DOH 2003). Winning Ways: Working together to reduce health care associated infection in England
3. Department of Health (DOH 2005). Saving Lives: A delivery programme to reduce health care associated infection including MRSA
4. Goodwin M, Carlson I (1993) The peripherally inserted catheter: a retrospective look at 3 years of insertions, Journal of Intravenous Nursing, 16 (2) 92-103
5. Hadaway L (1998) Catheter connection, Journal of Vascular access devices 3 (3), 40.
6. INS (2000) Infusion Nursing Standards of Practice, Journal of Intravenous Nursing 23 (6S) supplement
7. Todd J (1998) Peripherally inserted central catheters. Professional Nurse 13(5) 297-302
8. Jones A (2004) Dressings for the Management of Catheter Sites – A review. JAVA, Vol. 9 No 1, 1-8.
9. Campbell H, Carrington M (1999) Peripheral IV cannula dressings: advantages and disadvantages. British Journal of Nursing, 8(21):1420-1422, 1424-1427.
10.Treston-Aurand J et al (1997) Impact of dressing materials on central venous catheter infection rates. Journal of Intravenous Nursing 20(4):201-206.
11.Wille JC (1993) A comparison of two transparent film-type dressings in central venous therapy. Journal of Hospital Infection 23(2):113- 121
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
54Disconnection of A m bulat o r y Chemothe r a p y (In f usor/ Infuser) f rom Central V enous A ccess D e v i c e ( D S T 1)
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Action RationaleEquipment Required Dressing Pack containing sterile towel and gloves 10ml syringes x 2 or 20ml syringe x 1Chlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated wipe (Sani Cloth) 20ml 0.9% Sodium Chloride for injection prefilled syringe (or ampoules)5ml Heparin10units/ml in 0.9% Sodium Chloride One blue needle/filter strawSharps container Surgical tape, Alcohol hand rub, Needle-free system Plastic apronPlastic bag for empty cytotoxic chemotherapy infusor Luer lock stopper for Infusor
HEPARINISED SALINE WITH OPEN ENDED CATHETER
10 ml syringes should always be used. Smaller syringe sizes may damage the catheter (Hadaway 1998)
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust policy for
the administration of medications. Before the procedure begins make sure that your hands are washed and dried thoroughly and
that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packaging is
intact and in date. Take equipment trolley to patient. Inspect the catheter exit site for signs of skin discolouration or signs of infection e.g. exudate
Ensures patient compliance and reduces anxiety
Reduce the risk of infection, to avoid contamination
To maintain asepsis
Luer lock stopper will prevent leakage of chemotherapy from infusor this is now a sealed unit
55
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide.
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using a non
touch technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline (if required) and
place near to but not on the sterile field. Ensure easy access to the needle free system. Decontaminate hands. Put on sterile gloves. Connect needle/ filter straw to the syringe. Place sterile towel as near as possible to the catheter Draw up 20mls Normal Saline into a 20ml syringe and place on sterile field. Draw up 5ml
Heparinised Saline into 10ml syringe (if required) and place on sterile field. Place sterile towel as near as possible to the catheter. Hold the catheter with sterile gauze; disconnect Infusor from the access device. Apply
luer lock stopper to the end of the Infusor tubing and seal it in a plastic bag clearly labelled cytotoxic waste.
Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe, rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Attach syringe with 0.9% sodium chloride for injection, and flush the catheter with 20mls of 0.9% Normal saline using a push pause action clamping as the last ml of the solution is instilled into the catheter. Remove the syringe and discard.
If open ended catheter and this is the final dose of treatment for the day, repeat this procedure using 5ml Heparin 10units/ml in 0.9% sodium chloride clamping as the last ml of solution is instilled into the catheter to maintain catheter patency.
Remove the syringe and discard
56
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can easily damage the catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide or contact the hospital team who placed the device.
Clean the needle free connector again with a sani cloth, then wrap the end of the line in sterile gauze (gauze cot). Tape this to the patients’ chest/arm.
Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves and apron. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the trolley
that has been used during the procedure with multi-surface detergent wipes. Decontaminate hands. Document care in patient’s records.
57
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
58
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Care and Management of Totally Implanted Venous Access Device (TIVAD) e.g. Port-a-Cath (TIVAD1) 1.9% Sodium Chloride for injection flush and Heparin 100 iu/ml in 0.9% Sodium Chloride for injection Lock Heparin strengths may vary according to the frequency of the flushes required, refer to local policy
Action RationaleEquipment Required Dressing Pack containing sterile towel and gloves x2 10ml syringe x 1Chlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated applicator x 2 (Chloraprep)10ml 0.9% Sodium Chloride for injection prefilled syringes (or ampoules) 4ml Heparin 100iu/ml in 0.9% Sodium Chloride for injection.One Blue needle/filter straw Sharps containerSurgical tape Alcohol hand rubNon coring needle (e.g. Huber or gripper needle) with needle free systemHighly permeable dressing and securing device if receiving therapy other than for flushingPlastic apron Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust policy for
the administration of medications. Before the procedure begins make sure that your hands are washed and dried thoroughly and
that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times. Ensure working area is clean. Ensure all equipment is gathered before commencing the procedure and all packaging is
intact and in date. Take equipment/trolley to patient. . Inspect the catheter exit site for signs of skin discolouration or signs of infection, e.g. exudate
from exit site. Check observation and VIAD chart for any indications of infection or
Ensures patient compliance and reduces anxiety
Reduce the risk of infection, to avoid contamination
To maintain asepsis
59
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using a non
touch technique, ensuring no contamination of aseptic field. Ensure easy access to the needle free system. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline and place near
to but not on the sterile field Decontaminate hands Put on sterile gloves. Connect needle or filter straw to the syringe. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up 4ml
Heparinised Saline 100iu/ml into 10ml syringe and place on sterile field.
Place sterile towel as near as possible to the catheter insertion site. Prime the non-coring needle device including its tubing with 0.9% Sodium Chloride and
clamp extension tube, remove syringe. Remove anaesthetic cream if used, locate septum of TIVAD by palpation, remove gloves. Decontaminate hands, then apply new pair of gloves Clean the skin covering the TIVAD with Chlorhexidine Gluconate 2% in 70% Isopropyl
alcohol impregnated applicator (Chloraprep). Allow to dry. Remove needle cover from non-coring needle device. Insert the non-coring needle at 90-
degree angle through the skin into the septum of the TIVAD until the needle comes into contact with the metal backing.
Needle free device must be cleaned prior to reattaching syringe thoroughly scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe, rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe over a period of 30 seconds. Allow to dry.
60
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Attach syringe with 0.9% Sodium Chloride flush and aspirate enough blood to colour the solution, then inject the flush using a push/pause action, clamping as the last ml of solution is instilled into the catheter.
If there is no flash back of blood or if there is swelling around the TIVAD site assess for correct needle placement, remove the needle and re-access.
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can damage the catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide or contact IV access team.
Following successful saline flush, repeat the flushing procedure using the 4mls of Heparin sodium (100 iu/ml).
If TIVAD was accessed for flushing purposes only, remove the needle and apply pressure over puncture site for a few minutes until bleeding stops.
If the needle is to remain in situ ensure the needle is secured using steri-strips and appropriate semi permeable transparent IV dressing.
Clean the needle free connector again with a sani cloth, then wrap the end of the line in sterile gauze (gauze cot). Tape this to the patient’s arm/chest.
Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the trolley
that has been used during the procedure with multi-surface detergent wipes Decontaminate hands Document care in patient’s records.
60To t al l y Impl a n t ed V e nous A ccess De v i c e ( T I V A D ) e.g. P or t - a - Cath Blood sampling ( TI V A D2)
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Action RationaleEquipment Required Dressing Pack containing sterile towel and gloves x2 10ml syringes x 3,Chlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated applicator x 2 (Chloraprep)Chlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated wipes x 2 (Sanicloth) 10ml 0.9% Sodium Chloride for injection prefilled syringes (or ampoules)4ml Heparin 100iu/ml in 0.9% Sodium Chloride One blue needle/filter strawSharps container Surgical tape Alcohol hand rubNon coring needle (e.g. Huber or gripper needle) with needle free system Plastic apronSemi-permeable transparent IV dressing and securing device if receiving therapy other than for flushing Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust policy for
the administration of medications. Before the procedure begins make sure that your hands are washed and dried thoroughly and
that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times. Ensure working area is clean. Ensure all equipment is gathered before commencing the procedure and all packaging is
intact and in date. Take equipment/trolley to patient. Inspect the catheter exit site for signs of skin discolouration or signs of infection, e.g. exudate
from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free.
Ensures patient compliance and reduces anxiety
Reduce the risk of infection, to avoid contamination
To maintain asepsis
61
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using a non touch
technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline and place near
to but not on the sterile field Decontaminate hands Put on sterile gloves. Connect needle or filter straw to the syringe. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up 4ml
Heparinised Saline 100iu/ml into 10ml syringe and place on sterile field. Place sterile towel as near as possible to the catheter insertion site. Prime the non-coring needle device including its tubing with 0.9% Sodium Chloride and
clamp extension tube, remove syringe. Remove anaesthetic cream if used, locate septum of TIVAD by palpation, remove gloves. Decontaminate hands, then apply new pair of gloves Clean the skin covering the TIVAD with Chlorhexidine Gluconate 2% in 70% Isopropyl
alcohol impregnated applicator (Chloraprep). Allow to dry. Repeat with second Chloraprep, allow to dry. Remove needle cover from non-coring needle device. Insert the non-coring needle at 90-
degree angle through the skin into the septum of the TIVAD until the needle comes into contact with the metal backing.
Needle free device must be cleaned prior to reattaching syringe – thoroughly scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe, rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe over a period of 30 seconds. Allow to dry.
Attach empty 10ml syringe unclamp and aspirate 3-5ml of blood. If there is no flash back of blood or if there is swelling around the TIVAD site assess for correct needle placement,
62
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
remove the needle and re-access. NEVER FORCE THE SOLUTION INTO THE CATHETER, this can damage the catheter.
The solution should flow easily. If resistance felt refer to trouble shooting guide or contact IV access team.
Clamp catheter and remove the syringe and discard the sample. If unable to obtain blood flush the catheter as directed below. Using a second syringe, take amount of blood required for analysis then flush the port as directed below.
Attach syringe with 0.9% Sodium Chloride flush and inject the flush using a push/pause action, clamping as the last ml of solution is instilled into the catheter.
Following successful saline flush, repeat the flushing procedure using the 4mls of Heparin sodium (100 iu/ml).
If TIVAD was accessed for flushing purposes only, remove the needle and apply pressure over puncture site for a few minutes until bleeding stops.
If the needle is to remain in situ ensure the needle is secured using steri-strips and appropriate highly permeable dressing.
Clean the needle free connector again with a sani cloth, then wrap the end of the line in sterile gauze (gauze cot). Tape this to the patients’ arm.
Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the trolley
that has been used during the procedure with multi-surface detergent wipes Decontaminate hands Document care in patient’s records.
63
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Totally Implanted Venous Access Device (TIVAD) e.g. Port-a-Cath Administration of antibiotics/infusion/additives (TIVAD3) Heparin strengths may vary according to the frequency of the flushes required, refer to local policy
Action RationaleEquipment Required Dressing Pack containing sterile towel and gloves x2 10ml syringes x 2Chlorhexidine Gluconate 2% in 70% Isopropyl alcohol impregnated applicator 10ml 0.9% Sodium Chloride for injection prefilled syringe or ampoule5ml Heparin 10units/ml in 0.9% Sodium Chloride for injection. Two green needles/filter straw. Sharps containerSurgical tape, Alcohol hand rubNon coring needle (e.g. Huber or gripper needle) with needle free systemHighly permeable dressing and securing device if receiving therapy other than for flushingPlastic apronAntibiotics/additives/infusion as prescribed
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust policy
for the administration of medications. Medication reconstitution should be performed in a clean clinical environment. This may
be performed in an area designated for drug preparation or at the patient’s bedside as part of this procedure.
Before the procedure begins make sure that your hands are washed and dried thoroughly and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times. Ensure working area is clean. Ensure all equipment is gathered before commencing the procedure and all packaging is
intact and in date.
Ensures patient compliance and reduces anxiety
Reduce the risk of infection, to avoid contamination
To maintain asepsis
64
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Take equipment/trolley to patient. . Inspect the catheter exit site for signs of skin discolouration or signs of infection, e.g.
exudate from exit site. Check observation and VIAD chart for any indications of infection or complications. Ensure the intravenous access device has been comfortable and pain free. Observe for any swelling of the arm/neck. If you suspect any problems please contact the hospital team who placed the catheter for advice. Refer to trouble-shooting guide
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using a
non touch technique, ensuring no contamination of aseptic field. Snap the top from ampoules of Normal Saline 0.9% and Heparinised Saline and
place near to but not on the sterile field Remove dust cap from antibiotic vial/vials and place near to but not on sterile the field. Decontaminate hands Put on sterile gloves. Connect needle or filter straw to the syringe. Draw up 10mls Normal Saline into a 10ml syringe and place on sterile field. Draw up 5ml
Heparinised Saline into 10ml syringe and place on sterile field. Reconstitute antibiotics in accordance with manufacturer’s guidelines (as appropriate) Place sterile towel as near as possible to the catheter insertion site. Prime the non-coring needle device including its tubing with 0.9% Sodium Chloride and
clamp extension tube, remove syringe. Remove anaesthetic cream if used, locate septum of TIVAD by palpation, remove gloves. Decontaminate hands, then apply new pair of gloves Clean the skin covering the TIVAD with Chlorhexidine Gluconate 2% in 70% Isopropyl
alcohol impregnated applicator (Chloraprep). Allow to dry. Repeat with second Chloraprep, allow to dry.
Remove needle cover from non-coring needle device. Insert the non-coring needle at 90- degree angle through the skin into the septum of the TIVAD until the needle comes into contact with the metal backing.
Needle free device must be cleaned prior to reattaching syringe – thoroughly scrub the
65
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
hub of the needle free system with 2% Chlorhexidine impregnated wipe, rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe over a period of 30 seconds. Allow to dry.
Attach syringe with 0.9% Sodium Chloride, aspirate enough blood to colour the solution and inject the flush using a push pause action clamping as the last ml of the solution is instilled into the catheter. Remove the syringe and discard.
If there is no flash back of blood or if there is swelling around the TIVAD site assess for correct needle placement, remove the needle and re-access.
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can damage the catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide or contact IV access team.
Following successful 0.9% Sodium Chloride for injection flush, administer antibiotics/infusion/additives as prescribed following local Trust Policy
Flush the catheter again with the appropriate volume of 0.9% Sodium Chloride for injection, using a push/pause action, clamping as the last ml of the solution is instilled into the catheter
Repeat the flushing technique using 5mls of Heparin 10 units/ml in 0.9% Sodium Chloride, using a push/pause action, clamping as the last ml of the solution is instilled into the catheter
If TIVAD was accessed for flushing purposes only, remove the needle and apply pressure over puncture site for a few minutes until bleeding stops.
If the needle is to remain in situ ensure the needle is secured using steri-strips and appropriate highly permeable dressing.
Clean the needle free connector again with a sani cloth, then wrap the end of the line in sterile gauze (gauze cot). Tape this to the patients’ arm.
Ensure that the catheter is secure and comfortable. Remove dressing towel and discard. Remove gloves. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the
trolley that has been used during the procedure with multi-surface detergent wipes Decontaminate hands Document care in patient’s records
66
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Flushing and administration of IV medication via Peripheral Cannula (PCN1)
*All peripheral cannulas should be assessed every 8 hours using a cannula site assessment form as per organisational policy.*They require at least a 5ml flush of 0.9% Sodium Chloride for injection before and after the administration of medications.*Syringes smaller than 5ml should be avoided where possible as they can exert excessive force and cause trauma.*Three way taps should not be used on peripheral cannulas, if required, extension sets with needle free systems must be used.
*Administration sets should be changed as per manufacturer’s guidelines . Infusion sets used for blood products, blood and lipid emulsion (TPN), which should be changed up to a maximum of 24 hours. Change giving set immediately upon suspected contamination or when the integrity of the product or system has been compromised.* A semi permeable dressing should be used at all times to secure the cannula.
A
ction RationaleEquipment Required Patients drug prescription and administration record Dressing Pack containing sterile towel and gloves x1 10ml syringes x 2Chlorhexidine Gluconate 2% in 70% Isopropyl alcohol10ml 0.9% Sodium Chloride for injection prefilled syringe (or ampoules) IV medication to be administeredOne blue needle/filter straw. Sharps container Alcohol hand rubSemi-permeable transparent IV dressing Plastic apron
Explain the procedure to the patient. Ensure that valid consent is gained. Check the patient identity, prescription and flush required in accordance with trust policy
for the administration of medications. Medication reconstitution should be performed in a clean clinical environment. This may
be performed in an area designated for drug preparation or at the patient’s bedside as part
Ensures patient compliance and reduces anxiety
Reduce the risk of infection, to avoid contamination
67
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
of this procedure. Before the procedure begins make sure that your hands are washed and dried thoroughly
and that they continue to be decontaminated during the procedure. A plastic apron should be worn.
Maintain aseptic technique at all times Ensure working area is as clean as possible. Ensure all equipment is gathered before commencing the procedure and all packaging
is intact and in date. Take equipment/ trolley to patient. Inspect the cannula exit site for signs of skin discolouration, inflammation or any signs
of infiltration of fluid in tissues (using a phlebitis score tool). Ensure the intravenous access device has been comfortable and pain free. If complications evident do not use cannula, remove, document and resite cannula.
Open sterile pack and use a non-touch technique to place inner pack onto clean working area.
Decontaminate hands. Open out sterile pack to create an aseptic field. Open remaining equipment using a
non touch technique, ensuring no contamination of aseptic field. If a bolus is to be administered then the vial should also be placed next to aseptic field. Ensure easy access to the needle free system. Decontaminate hands Put on sterile gloves. Connect needle or filter straw to the syringe. Snap the top from ampoules of Normal Saline 0.9% and place near to but not on
the sterile field Decontaminate hands Put on sterile gloves. Connect needle or filter straw to the syringe. Draw up 5mls Normal Saline into a 10ml syringe and place on sterile field and repeat. Reconstitute antibiotics in accordance with manufacturer’s guidelines (as appropriate) Place sterile towel as near as possible to the catheter. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe, rubbing
To maintain asepsis
To prevent needle stick injury
To prevent contamination
To ensure catheter patency and prevent complications associated with extravasation.
68
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Attach syringe with 0.9% sodium chloride for injection, inject 5ml flush using a push pause action clamping as the last ml of the solution is instilled into the cannula. Remove the syringe and discard.
NEVER FORCE THE SOLUTION INTO THE CATHETER, this can easily damage the catheter. The solution should flow easily. If resistance felt refer to trouble shooting guide or contact IV access team.
Administer IV antibiotics/infusion/additives as prescribed following trust policy. Flush cannula again with 5ml 0.9% Normal Saline using a push/pause action. Remove the syringe and discard. Clean the needle free connector again with a sani cloth and allow to dry. Ensure that the cannula is secure and comfortable. Remove dressing towel and discard. Remove gloves and apron. Wash hands. Clear away equipment disposing of waste as per organisational policy. Wipe down the
trolley that has been used during the procedure with multi-surface detergent wipes. Decontaminate hands. Document drug administration in in-patients records. Record cannula site assessment as per organisational policy.
69
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Changing a Needle-free Connector (NFS1)
This procedure should be carried out in combination with routine line flushing. The frequency of the change of the Needle Free connector is determined by the number of uses, with reference to the manufacturer’s guidelines.
Action RationaleEquipment Required
Needle-free I/V access connector.
In conjunction with line flushing procedure:
Maintain aseptic technique at all times Clamp the catheter. Remove the needle free connector and discard. Scrub the hub of the needle free system with 2% Chlorhexidine impregnated wipe,
rubbing from the top of the needle free connector to the sides. Do this four times using different parts of the wipe, over a period of 30 seconds. Allow to dry.
Connect the new needle-free system to the catheter securely.
Reduce the risk of infection, to avoid contamination
70
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Trouble Shooting Guide
May 2012
For NHS North West
Intravenous Access Care and Maintenance
In Hospital and at Home
Developed byCollaborative Intravenous Nursing
Services (CINS)
71
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
EXIT SITE INFLAMMATION/PHLEBITIS
PHLEBITIS: PAINFUL INFLAMMATION ALONG VENOUS PATH IN WHICH VASCULAR ACCESS DEVICE IS PLACED
Signs & Symptoms
UnresolvedResolved
Action
Raised temperature Complaints of pain on flushing or
infusing. Vein hard on palpation Swelling at and above exit site Change in colour or tenderness at site
or along the vein. Exudate present at IV exit site Raised WBC
PROCEED WITH CAUTION AS
LONG AS THERE ARE NO OTHER
COMPLICATIONS OR PAIN
Monitor for signs of infection and take swab from exit site ifexudate presentRe-site cannula using larger vein above original site, avoiding joints to avoid further episodes of phlebitisSeek medical advice or contact clinical nurse specialistIf worsening then possible removal of VAD following discussion with specialist nurse or doctor
Increase
volume of diluent in case of chemical phlebitis and
administer at a slower rate, seek advice from pharmacy Advise patient to apply hot/cold compresses to affected area Redress and secure device using skin fixation device and
72
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
INFILTRATION AT VASCULAR ACCESS DEVICE SITE
Signs & Symptoms
Unresolved
Resolved
Actions
Burning sensation or swelling in subcutaneoustissue BlanchingBurning or discomfort at IV site Cool skin around IV siteSlow or continuing flow rate even when vein is occludedSwelling at and above the IV site Tight feeling at the IV siteNeck swelling
S
top the infusion immediately
Elevate limb to reduce oedema (if peripheral line) Remove VAD and apply pressure Re-site VAD above affected site Seek medical help if evidence of infiltration Advise patient to seek medical help if they experience
CONTINUE TREATMENT USING NEWLY SITED VAD
MONITORING CONTINUALLY FOR SIGNS OF
EXTRAVASATION
IF SYMPTOMS PERSISTS FOLLOWING REMOVAL OF
CANNULA, SEEK MEDICAL HELP OR URGENT ADVICE
FROM IV NURSE SPEVIALIST.
73
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
SYSTEMIC INFECTION Signs & Symptoms
PROCEED WITH CAUTION AS LONG AS
THERE ARE NO OTHER
COMPLICATIONS OR PAIN
Unresolved
Seek advice from IV specialist nurse, physician and Medical Microbiology
Assess need for VAD and patient's immune system Swab catheter site, any wound, sputum and urine Line lock to salvage line if clinically well. Consult specialist nurse or
seek medical help.
M
onitor site daily
Continue to use strict asepsis and always use needle-
Resolved
Actions
Fever and chills without other apparent reasonMalaiseNausea and vomiting Low grade pyrexiaUnresponsive to broad spectrum antibiotics HeadacheMay be no evidence of sepsis at catheter site Raised WBC and Raised CRPMay be discharge from exit site High suspicion of infection
74
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Care Plans
September 2014
For NHS North West
Intravenous Access Care and Maintenance
In Hospital and at Home
Developed byCollaborative Intravenous Nursing
Services (CINS)
75
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
FOR CARE OF PERIPHERAL VENOUS CANNULA.
The care plan is designed to be used in conjunction with CINS Guidelines for vascular devices.
Manufacturer’s specific recommendations should be noted and adhered to by individual practitioners.
Patient addressograph label / patient name
numbering.Identify site/s by
SITE NUMBER
DATE TIME COLOUR/GAUGE
REASON FOR SITING
CONSENTY/N
SIGNED REMOVED DATE
SIGNED
Type of device Risks Actions Variations / Comments SIGN
76
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
PERIPHERAL VENOUS CANNULA
Infection due to loss of skin integrity
Site clean and protected with sterile dressing as per CINS guidelines.
Minimum of 8 hourly inspection of site for signs of inflammation or infection.
Observe patient for signs of line infection (VIP score)
When VIP score 2 or above remove promptly.
Ensure administration lines are changed in line with local policy.
Replace any infusates with additives and their administration lines at 24hrs if constituted in ward environment.
Label infusion lines with date for renewal.
Air embolus Recommend all attachments are needle free devices and are securely fastened. This guideline does not promote the use of 3 way taps.Change needle free systems as indicated by manufacturers instructionsEnsure air dispelled from medication/flushes/ infusates prior to administration.Occlusion of lumen. Maintain patency via 0.9% Sodium Chloride for injection flushes as per CINS guidelines, post drug/infusion administration.
Ensure compatibility of drugs/infusates to avoid precipitation.
If difficult to flush then remove/re-assess.Bleeding from site / line itself.
Observe for signs of bleeding from site.
77
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Upon removal of cannula ensure adequate pressure is applied to site for cessation of bleeding.
If bleeding problematical check clotting times.Line displacement Check each time line accessed for signs of
displacement (extravasation and/or infiltration). Remove immediately if displaced.
Anchor lines to avoid accidental displacement Using fixation devices as in
Line in situ when no longer required.
Ensure prompt removal when line no longer required.
78
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
PATIENT CARE PLAN FOR CARE OF NON TUNNELLED CENTRAL LINE.
This care plan applies to patients with the following central lines:
subclavian jugular femoral
The care plan is designed to be used in conjunction with CINS Guidelines for vascular devices.
Manufacturer’s specific recommendations should be noted and adhered to by individual practitioners.
Patient addressograph label/patient name
REASON FOR INSERTION…
DEVICE TYPE…
DATE OF INSERTION…
Named Nurse or Advisor details….
Review Dates:
Date Comments
79
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Type of device Risks Actions Variations / Comments SIGNInfection due to loss of skin integrity
Site clean and protected with sterile dressing as per CINS guidelines.
Minimum of 8 hourly inspection of exit site for signs of inflammation or infection. Do not remove dressing unless soiled
Take swab for culture and sensitivity if indicated
Check weekly or at each visit if in community setting
Visual Infusion Phlebitis scored (VIAD) See chart
Observe patient for signs of line infection (pyrexia/raised WCC)
If clinically unstable and patient has had rigors, take blood cultures from line and independent venous sample
Assess medical condition prior to removal of line
Send line tip for culture and sensitivity following removal, in community only send if line sepsis suspected
Ensure administration lines in place following local policy.
Replace any infusates with additives and their administration lines up to a max of 24hrs if constituted in ward environment.
Label infusion lines with date for renewal. Change add-on devices at same time as
administration sets or as soon as integrity is compromised. Use needle free systems and avoid 3 way tapsAir embolus Use Needle-free systems
Ensure air dispelled from medication/ flushes/infusates prior to administration.
Assess need for infusion pumpOcclusion of lumen. Maintain patency via 0.9% Sodium Chloride for injection flushes as per CINS
80
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
guidelines, Pre & post drug / infusion administration. Use heparinised saline as CINS guidelines if open ended catheter
Ensure compatibility of drugs/infusates to avoid precipitation.
Ensure weekly flushes when not in use. Use needle-free system according to CINS guidelines using positive pressure flush
Ensure regular flushes when lumens not in use.Bleeding from site /
line itself. Observe for signs of bleeding from site. Apply pressure above dressing Ensure add on devices if needed
are securely fastened. Ensure clotting studies in
acceptable range prior to removal of line.Line migration /
displacement Check notes to ensure medical staff
have documented line is in correct place and safe to use.
Ensure line securely sutured. Check each shift for signs of line
migration, e.g. visible lumens outside of exit point.
Anchor lines to avoid accidental displacement.
If in doubt do not use line Ensure patient is aware of any potential
problems which may occur. So they can report them immediately
Line in situ when no longer required.
Daily review on need for line/ consideration of change to more appropriate line for patient.
Daily documentation on need for line documented in nursing/medical notes.
Ensure prompt removal when line no longer required.
81
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
EVALUATION RECORD
DATE EVALUATION SIGN, DESIGNATION
82
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
PATIENT CARE PLAN FOR CARE OF SKIN TUNNELLED CENTRAL CATHETER
The care plan is designed to be used in conjunction with CINS Guidelines for vascular devices.
Manufacturer’s specific recommendations should be noted and adhered to by individual practitioners.
Patient addressograph label/patient name
REASON FOR INSERTION…
DEVICE TYPE…
DATE OF INSERTION…
Named Nurse or Advisor details….
Review Dates:
Date Comments
83
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Type of device Risks Actions Variations / Comments SIGNInfection due to loss of skin integrity Site clean and protected with
sterile dressing as per CINS guidelines.
Minimum of 8 hourly inspection of exit site for signs of inflammation or infection. Do not remove dressing unless soiled.
Take swab for culture and sensitivity if indicated
Check weekly or at each visit if in community setting
Visual Infusion Phlebitis scored (VIAD) See chart
Observe patient for signs of line infection (pyrexia / raised WCC)
If clinically unstable and patient has had rigors, take blood cultures from all lumens from the line and independent venous sample. Refer to medical team.
If line is removed, Send tip for culture and sensitivity
Ensure administration sets are changed as per local policy.
If administration sets are disconnected from the access device at any time they should be discarded.
Replace any infusates with additives and their administration lines up to a max of 24hrs if constituted in ward environment.
Label infusion lines with date for renewal. Change add-on devices at same time as
administration sets or as soon as integrity is compromised. Use needle-free systems and avoid 3 way tapsAir embolus Use Needle-free systems
Ensure air dispelled from medication/
84
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
flushes/infusates prior to administration. Assess need for infusion pump
Occlusion of lumen. Maintain patency via 0.9% Sodium Chloride for injection flushes as per CINS guidelines, Pre & post drug/ infusion administration. Use Heparin Sodium as CINS guidelines if open ended catheter
Ensure compatibility of drugs/infusates to avoid precipitation.
Ensure weekly flushes when not in use. Use needle-free system according to CINS guidelines using positive pressure flushBleeding from site /
line itself. Observe for signs of bleeding from site. Apply pressure above dressing Ensure add on devices/taps securely
fastened. Ensure clotting studies in
acceptable range prior to removal of line.Line migration /
displacement Check notes to ensure medical staff
have documented line is in correct place and safe to use
Check each time line accessed for signs of line migration
Anchor lines to avoid accidental displacement using fixation devices as in CINS guidelines.
If in doubt do not use line and ensure patient is aware of problems which may occur.
Line in situ when no longer required.
Ensure prompt removal when line no longer required.
85
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
EVALUATION RECORD
DATE EVALUATION SIGN, DESIGNATION
86
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
PATIENT CARE PLAN FOR CARE OF PERIPHERAL MIDLINE
The care plan is designed to be used in conjunction with CINS Guidelines for vascular devices.
Manufacturer’s specific recommendations should be noted and adhered to by individual practitioners.
Patient addressograph label / patient name
REASON FOR INSERTION…
DEVICE TYPE…
DATE OF INSERTION…
Named Nurse or Advisor details….
Review Dates:
Date Comments
87
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Type of device Risks Actions Variations / Comments SIGNInfection due to loss of skin integrity
Site clean and protected with sterile dressing as per CINS guidelines.
Minimum of daily inspection of exit site for signs of inflammation or infection. Do not remove dressing unless soiled.
Take swab for culture and sensitivity if indicated
Check weekly or at each visit if in community setting
Visual Infusion Phlebitis scored (VIAD) See chart
Observe patient for signs of line infection (pyrexia/raised WCC)
If clinically unstable and patient has had rigors, take blood cultures from line and independent venous sample
Assess medical condition prior to removal of line
Send line tip for culture and sensitivity following removal, in community only send if line sepsis suspected
Ensure administration lines in place following local policy..
Replace any infusates with additives and their administration lines up to a max of 24hrs if constituted in ward environment.
Label infusion lines with date for renewal. Change add-on devices at same time as
administration sets or as soon as integrity is compromised. Use needle-free systems and avoid 3 way tapsAir embolus Use Needle-free systems
Ensure air dispelled from medication/ flushes/infusates prior to administration.
88
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Assess need for infusion pump
Occlusion of lumen. Maintain patency via 0.9% Sodium chloride for injection flushes as per CINS guidelines, Pre & post drug/ infusion administration. Use heparinised saline as CINS guidelines if open ended catheter
Ensure compatibility of drugs/infusates to avoid precipitation.
Ensure weekly flushes when not in use. Use needle-free system according to CINS guidelines using positive pressure flushBleeding from site /
line itself. Observe for signs of bleeding from site. Apply pressure above dressing Ensure add on devices/taps securely
fastened. Ensure clotting studies in
acceptable range prior to removal of Line migration / displacement
Check notes to ensure medical staff have documented line is in correct place and safe to use
If line disconnected for any reason then discard
Check each time line accessed for signs of line migration
Anchor lines to avoid accidental displacement using fixation devices as in CINS guidelines.
If in doubt do not use line and ensure patient is aware of problems which may occur.
Line in situ when no longer required.
Ensure prompt removal when line no longer required.
89
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
EVALUATION RECORD
DATE EVALUATION SIGN, DESIGNATION
90
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
PATIENT CARE PLAN FOR CARE OF PERIPHERALLY INSERTED CENTRAL CATHETER (PICC)
The care plan is designed to be used in conjunction with CINS Guidelines for vascular devices.
Manufacturer’s specific recommendations should be noted and adhered to by individual practitioners.
Patient addressograph label/patient name
REASON FOR INSERTION…
DEVICE TYPE…
DATE OF INSERTION…
Named Nurse or Advisor details….
Review Dates:
Date Comments
91
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Type of device Risks Actions Variations / Comments SIGNInfection due to loss of skin integrity
Site clean and protected with sterile dressing as per CINS guidelines.
Minimum of 8 hourly inspection of exit site for signs of inflammation or infection. Do not remove dressing unless soiled
Take swab for culture and sensitivity if indicated
Check weekly or at each visit if in community setting
Visual Infusion Phlebitis scored (VIAD) See chart
Observe patient for signs of line infection (pyrexia/raised WCC)
If clinically unstable and patient has had rigors, take blood cultures from line and independent venous sample
Assess medical condition prior to removal of line
Send line tip for culture and sensitivity following removal, in community only send if line sepsis suspected
Ensure administration lines in place following local policy.
Replace any infusates with additives and their administration lines up to a max of 24hrs if constituted in ward environment.
Label infusion lines with date for renewal. Change add-on devices at same time as
administration sets or as soon as integrity is compromised. Use needle free systems and avoid 3 way tapsAir embolus Use Needle-free systems
Ensure air dispelled from medication/ flushes/infusates prior to administration.
92
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Assess need for infusion pumpOcclusion of lumen. Maintain patency via 0.9% Sodium
Chloride for injection flushes as per CINS guidelines, Pre & post drug/ infusion administration. Use heparinised saline as CINS guidelines if open ended catheter
Ensure compatibility of drugs/infusates to avoid precipitation.
Ensure weekly flushes when not in use. Use needle-free system according to CINS guidelines using positive pressure flush
Bleeding from site / line itself.
Observe for signs of bleeding from site. Apply pressure above dressing Ensure add-on devices/taps securely
fastened. Ensure clotting studies in
acceptable range prior to removal of line.
Line migration / displacement
Check notes to ensure medical staff have documented line is in correct place and safe to use
If line disconnected for any reason then discard
Check each time line accessed for signs of line migration
Anchor lines to avoid accidental displacement using fixation devices as in CINS guidelines.
If in doubt do not use line and ensure patient is aware of problems which may occur.
.
Line in situ when no longer required.
Ensure prompt removal when line no longer required.
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
93
EVALUATION RECORD
DATE EVALUATION SIGN, DESIGNATION
1
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Appendix 1
Guideline recommendationsTo be reviewed following NICE guidance
The guidelines within this document should support the intravenous care and management of adults, for guidance on the care of children please refer to the CINs paediatric guidelines. For guidance on the care of infants consult with your local paediatric specialists.
Recommend using Chlorhexidine Gluconate 2% in 70% Isopropyl alcohol available in applicator and impregnated wipes.
The clinician must ascertain whether the Catheter tip is open or closed. A closed device does not require Heparin sodium.
Heparinised saline recommended concentration 10 units in 1 ml
When Catheters are not in use they should be flushed with 10ml sodium chloride 0.9%. (5mls of Heparin 10 units/ml in 0.9% Sodium Chloride or 4mls of Heparin 100 units/ml in 0.9% Sodium Chloride [depending on type of line] as well if the catheter is open ended). This should be performed on a weekly or monthly basis following the maintenance guidelines.
For needle-free connectors, manufacturer’s guidance should be followed regarding when the device should be changed.
Reminder that hands must be washed and dried thoroughly before putting on disposable gloves and after removing sterile gloves.
If there is sensitivity to Chlorhexidine solution, Providone Iodine may be used as an alternative.
If manufacturer’s guides prevent the use of Alcoholic Chlorhexidine on certain types of IV access devices then 2% Aqueous Chlorhexidine should be used (see EPIC guidelines).
Ensure all interventions are recorded in the patient’s records as per organisational policy and NMC requirements.
Biopatch antimicrobial dressing with Chlorhexidine Gluconate (Johnson & Johnson) is recommend for use in patients with increased risk of line infection.
2
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
List of contributors to the Venous Access Guidelines
Name Organisation Job Title/RoleAlison Young Royal Liverpool & Broadgreen
University Hospital TrustNurse Consultant in Nutrition
Alison Smith Liverpool Community Health NHS Trust
Lead Nurse IV community team
Carol McCormick Clatterbridge Centre for Oncology Clinical Nurse Specialist IV and Interventional procedures
Christine Cain Wirral University Teaching Hospital NHS Foundation Trust
Paediatric Clinical Practice Development Nurse
Christine Roberts Sefton PCT / University Aintree Hospitals Foundation Trust
IV Therapy Lead Nurse
Coral Hulse Leighton Hospital Trust Nurse Consultant in Intensive careDesmond Collins Wirral University Teaching Hospital
NHS Foundation TrustSpecialist Nurse Paediatric HDU, Paediatric Resusitation Nurse
Helen Harker Royal Liverpool & Broadgreen University Hospitals NHS Trust
Senior Nurse in Intravascular access
Janine Grundy Warrington PCT Intravenous Therapy Team LeaderJo Marinas Royal Liverpool & Broadgreen
University Hospitals NHS TrustClinical Skills Manager
Name Organisation Job Title/RoleKaren Ellis University Aintree Hospitals
Foundation TrustClinical Skills / Practice Education Manager
Karen Selwood Alder Hey Children’s NHS Foundation Trust
Oncology Advanced Nurse Practitioner
Liz Collins Wirral University Teaching Hospital NHS Foundation Trust
Ward Manager Ward 11 Women & Children’s Division
Lorraine Smith Wirral University Teaching Hospital NHS Foundation Trust
Infection Control Nurse/Infection Control Surveillance Nurse Coordinator
Malcolm Smith Mid Cheshire Hospitals Foundation Trust
Clinical Skills Tutor
Rebecca Molyneux
Royal Liverpool & Broadgreen University Hospital Trust
Nurse Consultant in Infection Control
Ruth Glenn Halton & St Helens PCT IV Therapy Nurse PractitionerSara Melville Alder Hey Children’s NHS
Foundation TrustPaediatric IV Nurse Specialist
Shirley Smith Liverpool Community Health NHS Trust
Community IV Team Liverpool
Sue O’Hanlon Halton & St Helens CHS IV therapy Nurse Specialist
3
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Appendix 2
Merseyside & Cheshire Cancer Network
Network Guidance for the Prevention and Management of Extravasation Injuries (Revised Mar 08)
STOP! – Have you got the most up to date version of this policy?Always Check w w w . m ccn . nhs . u k before reading further.
Policy formulated and developed by the following:
Clatterbridge Centre for Oncology NHS Foundation Trust Countess of Chester Hospital NHS Foundation Trust North Cheshire Hospitals NHS TrustRoyal Liverpool & Broadgreen University Hospitals NHS Trust Royal Liverpool Childrens Hospital NHS TrustSouthport & Ormskirk Hospitals NHS Trust St Helens and Knowsley Hospital NHS TrustUniversity Hospital Aintree NHS Foundation TrustWirral University Teaching Hospitals NHS Foundation Trust
4
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
CONTENTS PAGE NUMBER
1 Introduction 3
2 Definition 3
3 Scope 4
4 Evidence Base 4
5 Causes 4
6 Risk Reduction 4
77.1
Recognition Symptoms
45
8 General Procedure for the Management of Extravasation or suspected Extravasation
5
9 Further notes on treatments for cytotoxic extravasations 6
1010.110.2
Extravasation Kits Contents Location
888
1111.111.2
Documentation & Reporting Local ProceduresGreen Card Reporting
888
12 References & Suggested Further Reading 9
Appendix 1 Classification of Cytotoxic Drugs according to their Potential to cause severe necrosis when extravasated
10
Appendix 2 Specific Antidotes in the management of peripheral extravasation
11
Appendix 3 Extravasation – Evidence behind recommendations 12
5
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
1. Introduction
The purpose of this document is to set out the Guidelines for the management of cytotoxic extravasation incidents within the Merseyside and Cheshire Cancer Network.
National and Regional standards that this document adheres to and should be read in conjunction with include:
Manual For Cancer Standards 2004 MCCN Guide to Care and Maintenance of Venous access devices incorporating the
Collaborative Intravenous Nursing Service guidelines for venous access devices for Cheshire and Merseyside NHS Northwest
Reference guide to Consent and Treatment, DH 2001Additionally, network and local policies that support and comply with this document have been developed. These include
Network guidelines for the safe prescribing, handling and administration of cytotoxic drugs
Network 24 hour telephone advice specification Local chemotherapy administration policies Local consent policies
This policy has been written using the best available current evidence and will be reviewed as other evidence becomes available.
2. DefinitionExtravasation is defined as the leakage of a vesicant drug or fluid from a vein into the surrounding tissue during intravenous administration1. A vesicant is defined as a drug or solution which has the potential to cause blistering, severe tissue damage and even necrosis if extravasated.2 Vesicants may cause damage to the surrounding tissue nerves, tendons or joints. This may be accompanied by pain, erythema, inflammation and discomfort, which, if left unrecognised or treated inappropriately can lead to necrosis and functional loss of the vein and possibly limb concerned3. Infiltration is the inadvertent administration of a non vesicant solution into surrounding tissues. While this may cause inflammation and discomfort, damage and necrosis rarely occurs.1
For clarity the term extravasation will be used to describe the inadvertent leakage of any drug or fluid into surrounding tissues.
Once an extravasation has occurred, the full extent of the injury may be unclear, and damage may continue for weeks or months. Any extravasation should be considered a medical emergency and a prompt, appropriate response is essential. The degree of injury can range from apparently insignificant erythema through to blistering, skin sloughing and severe necrosis, which often require corrective plastic surgery. Accurate documentation of the incident is essential. There is no National Standard of Practice.
6
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
3.0 ScopeThe aim of this document is to provide a framework based on current available evidence for the appropriate management of cytotoxic-inducedextravasation within the Merseyside and Cheshire cancer network. It includes paediatric practise.
Cytotoxic drugs may be divided in 5 categories based upon their propensity to cause extravasation injury. The drugs included in this policy are listed in appendix 1. However this list may not be exhaustive and it is the practitioner’s responsibility to recognise the potential for injury and appropriate management for any drug which they are administering2.
4.0 Evidence baseExtravasation is a condition that is often under-diagnosed, under-treated and unreported. The relevance of many published articles is difficult to assess because they often refer to isolated incidents that have been treated in an inconsistent way. Treatment recommendations in this policy have been made based on the best available evidence or where such evidence is lacking, based on a consensus of professional opinion from expert pharmacists, nurses, and doctors from the Merseyside and Cheshire Cancer Network and other network and professional body extravasation documents.For the evidence base for specific recommendations made in this policy see appendix 3.
5.1 Causes Dislodgement of the distal tip of the cannula into the tissues surrounding the vein. Constriction of the blood flow distal to the cannula tip which increases venous
pressure and allows fluid to leak from the hole in the vein made by the cannula. Inappropriate selection of the position and size of cannula and the length of time which
the cannula is left in situ. Practitioner unfamiliarity with the drug and the manufacturer’s recommendations for
administration.
6.1 Risk Reduction Only authorised practitioners who have been trained and are included on a register
may administer chemotherapy At all times the standards in local and network chemotherapy administration
policies must be adhered to. Particular care must be taken with the selection and positioning of the cannula. Drugs with the highest vesicant potential should be given first. All practitioners administering cytotoxic drugs must have an understanding of
the management of extravasation and know the contents and whereabouts of the extravasation kit.
If vesicant drugs are administered by a non ambulatory infusion pump then the pump must have appropriate pressure sensors that will give early warning of an occlusion
7.1 RecognitionIt is important that extravasation is not misdiagnosed because the treatment itself may involve the administration of drugs which themselves can cause further physical trauma to the patient, and may also potentiate extravasation. Early recognition is vital. Misdiagnosis often occurs when the practitioner fails to differentiate discolouration reactions in the vein,
7
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
venous shock, flare or phlebitis. Some cytotoxic drugs are coloured and if the selected vein lies superficial to the skin, the injection of a red coloured drug may cause local venous discolouration. 4
7.2 SymptomsSigns and symptoms of possible extravasation include:
pain, stinging, burning or any other acute change at the injection site. NB Children who are frightened of needing a new cannula may deny pain or discomfort.
Induration, erythema, venous discolouration or swelling at the injection site. No blood return is obtained. If this is found in isolation, other signs should be looked
for, as this can be misleading and has been implicated in a number of serious incidences. There are 2 ways in which the return of blood may be misleadingo If there has been an extravasation injury and the cannula has become displaced,
the act of trying to draw back blood to test for return may move the cannula back into the vein. Thus blood is returned and the vein appears patent. However, there is a hole in the vein wall in the proximity of the cannula tip and when administration of chemotherapy recommences, a larger and more significant extravasation injury will occur.
o Alternatively, the bevel of the needle can puncture the vein wall during venepuncture, allowing the drug to escape into the tissue while the lumen of the needle may still remain in the blood vessel and allow adequate blood return.4
there is increased resistance to administration once possible positional changes have been discounted
changes in infusion rate – Nb these may not be seen if using an infusion pump so close observation required.
8.0 General procedure for the management of extravasation or suspected extravasation
If extravasation is suspected, it is important to act quickly to prevent tissue necrosis. The practitioner who is responsible for the administration of the vesicant should recognise that an extravasation has occurred and initiate the procedure.
Immediate Management (Central and Peripheral)
Never apply pressure initially
Step 1 Stop the infusion or injection – Do not remove the venflon
Step 2 Seek assistance if needed
Step 3 Disconnect drip and aspirate as much drug as possible, trying also to draw some blood back into the cannula.
Step 4 Remove cannula with minimal pressure – if central or mixed chemotherapy administration inform consultant with a view to immediate plastic surgeon referral. Extravasations from portacath needle locking points may be treated as peripheral.
8
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Step 5 Mark the affected area
Step 6 Elevate the limb and encourage movement
Step 7 For Mustine , anthracyclines, other vesicants , vinka alkaloids, and other drugs FOLLOW SPECIFIC ANTIDOTE GUIDANCE. (See below for further notes)
Step 8 Inform consultant
Step 9 Provide analgesia if required
Step 10 Measure the area of extravasation, document any treatment as per local policy and photograph injury if possible
Step 11 Provide patient information leaflet with documented measurements of injury – The practitioner must be aware of the possibility of delayed injury. Ensure that the patient knows to contact chemotherapy unit if symptoms worsen or persist. Advise the patient to elevate the affected limb as often as possible for the next 2-3 days. Arrange a follow up appointment if needed.
Subsequent Steps
Step 12 Complete Green Card, trust incident form and any other local documentation as required. Send copy of green card to trust pharmacist who will send to the network pharmacist
Step 13 Consider referral to physiotherapist
Step 14 Refill extravasation kit – local policy to detail procedure for refill
9.1 Further notes on treatments for cytotoxic
extravasations See appendix 3 for evidence base for specific
treatments. Treatment principles
Localise and neutralise uses pulsed cold compression with or without a specific treatment to stop the further spread of the drug and prevent further injury.
Spread and dilute uses warm compression with or without hyaluronidase to facilitate dispersal of the extravasated drug thus reducing its concentration and potential for tissue damage.
As a general rule cold compression is used except in the case of vinca alkaloids where warm compression is used. The practitioner must check the specific antidote table (appendix 2) before proceeding with any intervention.
9
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Hyaluronidase: Dilute 1500 units of hyaluronidase in 2 ml of water for injection, or 0.9% sodium chloride. Gently massage the area to facilitate dispersal.
Sodium Thiosulphate: Infiltrate 1-3 ml of 3% isotonic sodium thiosulphate into the affected area using multiple ‘pin cushion’ injections. To achieve 3% sodium thiosulphate from the 50% vial in the extravasation kit, dilute 1.2 ml of 50% to 20 ml with water for injection.
Topical DMSO: apply 50% solution topically every 2 hours toThe extravasation site for 24 hours. Avoid contact with good skin. Do not cover the area. If blistering occurs discontinue use and seek further advice.
Surgical excision: Wide excision with use of grafts may be indicated if persistent pain 1-2 weeks after injury. Inadequate excision is associated with continuing necrosis at the margins, poor granulation and failure of engraftment.
Hypodermoclysis: Administering fluids under the skin.
Warm Compression W.C.C. Warm Continuous Compression. Apply firmly but without undue pressure a heat source (hot water bottle or small electrically heated blanket) to the area continuously for 24 hours. The heat source should not be in direct contact with the skin and a piece of dry gauze should be laid in between. This assists the natural dispersal of the drug.
Cold Compression: P.C.C Pulsed Cold Compress. Apply firmly but without pressure a cold source (crushed ice, flexible cold pack or cold bandage) intermittently (for 30 minutes in every 2 hours) over the area for the first 24 hours, unless advised otherwise. Place a piece of dry gauze between the skin and cold source.
Acidic Extravasations: If the extravasation has been misdiagnosed or the volume extravasated wrongly assessed, the treatment could lead to an alkali extravasation. If this secondary extravasation occurs, it is far more serious and the consequence far more devastating then those associated with venous extravasation. Caution and expert advice should be exercised before proceeding with this specific management.
Sodium Bicarbonate: Infiltrate with 1-3 ml of 2.1% sodium bicarbonate. 8.4% sodium bicarbonate must be diluted as follows. To achieve 2.1% sodium bicarbonate take 5ml of 8.4% sodium bicarbonate, add 5ml of water for injection, discard 5ml of this new solution and add a further 5ml of water for injection. Sodium bicarbonate is not in the extravasation kit. Do not use this antidote unless recommended by an expert. (Plastic surgeon)
Adapted from the National Extravasation Information Service 2004
SteroidsMany guidelines recommend the use of subcutaneous or intradermal steroids. However many reviews state that inflammation is not prominent in the aetiology of tissue necrosis. There is also evidence that subcutaneous or intradermal steroids may be harmful in high doses, are ineffective in certain extravasations and may increase the skin toxicity of vinca
10
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
alkaloids. For this reason, this policy does not recommend the routine use of subcutaneous steroids and injectable steroids are not included in the extravasation kit. Topical hydrocortisone 1% cream is unlikely to do harm and may reduce non-specific inflammation, except in vinca-alkaloid injuries 5
10.1 Extravasation Kits
Both the emergency policy and the extravasation kit should be simple and easy to follow to reduce the risk of inflicting further damage. It is necessary to hold a complete set of antidotes and hot and cold facilities in all areas where the administration of chemotherapy takes place.
10.2 Contents
Topical DMSO (dimethylsulfoxide solution 50%) Hyaluronidase 1500 units injection Hydrocortisone 1% cream Sodium thiosulphate 50% solution (DO NOT USE UNDILUTED – use as 3% solution),
only for units using mustine Sodium chloride 0.9% injection Water for injection Selection of needles, syringes, alcohol wipes, sterile gauze Directions to the nearest hot/cold pack Guide to immediate management including use of specific antidotes
It is the responsibility of the practitioner to ensure that they are familiar with the general policy and the extravasation kit.
10.3 Location(insert location of all extravasation kits)
Kits must be available in any area where intravenous chemotherapy is given.A laminated copy of the immediate management of extravasation should be available in all clinical areas and with the extravasation kit.Practitioners should liase with pharmacy to ensure timely refill of the kit after use.For CCO outreach clinics, CCO will be responsible for supplying the extravasation kits for use in the clinic. Local arrangements must be in place if CCO cannot provide any part of the kit e.g. warm/cold packs.
11.1 Documentation and reporting
11.2 Local proceduresFollow local procedures for documentation and clinical incident reporting. If possible photograph the injury. Documentation should include the drugs involved, size and location of cannula, procedure followed and any specific antidotes used, and outcomes.
11.3 Green Card ReportingMost information about the treatment of extravasation is anecdotal. The “Green Card” scheme should be used for reporting extravasation incidences, treatments and outcome. This
11
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
scheme is co-ordinated through the St.Chad’s Unit, City Hospital, Birmingham. Green cards can be filled in online
The aims of the Green Card are: to obtain accurate statistical information on the number of incidents categorised by
extravasating drug and type of treatment to collect data on treatment methods and antidotes being used for extravasation
incidents to obtain accurate information on the outcome of incidents to feedback information on the treatment and its
effectiveness Green Cards ask for the following information:
the drug or drugs involved how was it detected the extent of the problem drugs used in the treatment of the extravasation the procedure for treatment type of cannula used for the administration of the chemotherapy location and extent of the extravasation outcome
These reporting cards are user friendly. The information given can remain anonymous for the reporter, the patient and the Centre involved.
Reporting can be done online at http://www.extravasation.org.uk/Greenmenu.htm
Green cards should be available alongside the extravasation kit and can be obtained from http://www.extravasation.org.uk/Greenmenu.htm or by post from Extravasation Co-ordinator, c/o St Chad’s Unit, City Hospital, Dudley Road, Birmingham B1 8 7QH
If reporting online please print a copy of the form before submitting and send to the network pharmacist. If using a green card please make a copy and send to your trust pharmacist who will send it to the network pharmacist.
12 References and suggested further reading
1 Mallet and Dougherty (2004) The Royal Marsden Manual Handbook2 How, C and Brown J. (1998) Extravasation of cytotoxic chemotherapy from peripheral veins European Journal of Oncology Nursing 2 (1) 51-58
3 Hadaway L.C. (2001) Vesicant Extravasation. Nursing 31(8) 88
4 National Extravasation Information Service (2004) www.extravasation.org.uk accessed 19/04/2006
5 UKCCSG extravasation policy (2005)
12
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Appendix 1
CLASSIFICATION OF CYTOTOXIC DRUGS ACCORDING TO THEIR POTENTIAL TO CAUSE SEVERE NECROSIS WHEN EXTRAVASATED
Vesicants: Group 1
Exfoliants: Group 2
Irritants: Group 3
Inflammitants: Group 4
Neutrals: Group 5 (unlikely
tocause problems if extravasated)Amsacrine Aclarubicin Carboplatin Etoposide
Phosphate
Asparaginase
Carmustine Cisplatin (conc
>0.5mg/ml)
Etoposide Fluorouracil Bleomycin
Dacarbazine Daunorubicin
Liposomal
Irinotecan Methotrexate Cladribine
Dactinomycin Docetaxel Teniposide Raltitrexed Cyclophosphami
de
Daunorubicin Doxorubicin
Liposomal
Cytarabine
Doxorubicin Floxuridine bortezomib
Epirubicin Oxaliplatin Fludarabine
Idarubicin Topotecan Gemcitabine
Mitomycin Ifosfamide
Mitoxantrone Melphalan
Mustine Pentostatin
Rituximab
Paclitaxel Thiotepa
Plicamycin Beta-Interferons
Streptozocin Aldesleukin (IL-
2)
Treosulfan Trastuzumab
Vinblastine cisplatin
Vincristine alemtuzumab
Vindesine
Vinorelbine
Nb this list may not be exhaustive. It is the practitioners responsibility to know the vesicant potential of any drug not on this list Appendix 2
13
Appendix 2
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
Specific antidotes in the management of peripheral extravasation
Drug/class of drug
Warm/Cold compression
Specific antidote
Vinca Alkaloids Vincristine Vindesine Vinblastine Vinorelbine
Warm compression- apply for 24 hours
Hyaluronidase 1500 IUDraw up 1500IU hyaluronidase in 1 to
2ml water for injection or 0.9% sodium chloride. Inject 0.1 to 0.2ml subcutaneously at points of the compass around the circumference of the area of extravasation. Gently massage area to facilitate dispersal.
Mustine Apply cold pack intermittently for 30minutes in every 2 hours for 24 hours. Place a piece of dry gauze between skin and cold pack
3% Sodium Thiosulphate – Dilute the solution provided before use – dilute 1.2ml of 50% sodium thiosulphate to 20ml with water for injections.Infiltrate the site with 1 to 3ml of diluted solution using multiple “pin cushion” injections around the circumference of the area.Apply topical hydrocortisone 1% cream four times a day for the next 7 days or for as long as erythema persists
Anthracyclines Daunorubicn Doxorubicin Epirubicin Idarubicn
Mitoxantrone Mitomycin C
Apply cold pack intermittently for 30minutes in every 2 hours for 24 hours. Place a piece of dry gauze between skin and cold pack
Topical DMSO 50%Apply Topical DMSO 50% using a cotton bud every 2 hours at the extravasation site for 24 hours. Avoid contact with good skin. For the next 7 days apply DMSO50% every 6 hours alternating with topical hydrocortisone 1% cream every 3 hours. Do not use an occlusive cover. If blistering occurs, stop DMSO and seek further advice.
Any other cytotoxic drug (See appendix 1 for list.)
Automatic cold or warm compression is not required.However if symptoms warrant then use intermittent cold compression except in the case of oxaliplatin, cisplatin, or carboplatin when warm compression may be used.
No specific antidote neededIf signs of erythema persist then topical 1% hydrocortisone cream may be used. Apply sparingly to the affected area 4 times a day while symptoms persist.
14
Appendix 3
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
EXTRAVASATION – EVIDENCE BEHIND RECOMMENDATIONS
Controversy continues about appropriate antidote therapy and the situation is complicated by the inability to conduct controlled studies on human subjects. Ethical constraints and differences in tissue structure between human and animal skin are two of the biggest obstacles of antidote research. In this section the evidence behind the recommendations made in the monographs will be graded according to the definitions derived from US Agency for Health Care Policy and Research below.
Type and level of evidence Level Type of evidence
Ia Evidence obtained from meta-analysis of randomised controlledtrials.
Ib Evidence obtained from at least one randomised controlledtrial.
IIa Evidence obtained from at least one well-designed controlled
study without randomisation.
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study.
III Evidence obtained from well-designed non-experimentaldescriptive studies, such as comparative studies, correlation studies and case control studies.
IV Evidence from expert committee reports or opinions and/or clinical experiences of respected authorities.
A) Grade of Recommendation
Unfortunately, no antidote has so far received a clear validation in controlled clinical trials. Therefore, case reports and uncontrolled studies are still the only evidence for the role of antidotes in the clinical setting and, in some cases they do provide relevant cumulative
Gr a de Evidence Level
Recommendation
A Ia, Ib Required – at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing specific
B IIa, IIb, III Required – availability of well conducted clinical studies but no randomised clinical trials on the topic of recommendation.
C IV Required – evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities.Indicates absence of directly applicable clinical
st u dies o f g o o d q ual i t y .
15
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
experience. Due to the volume of the above studies the authors of this policy decided to use only reviews as evidence. The authors also reviewed other policies from the UK and contacted the manufacturer of each drug asking for their recommendations for the treatment of an extravasation with that particular drug.As a result most of the recommendations contained in this policy will be Grade B or C and will be a result of evidence obtained from reviews, other UK extravasation policies, and manufacturers.
Treatment RecommendationsEvidence
A. Apply cold pack, firmly but without pressure, intermittently for 30 minutes in very 2 hours over the area for the first 24 hours, unless advised otherwise. The cold pack should not be placed directly on the skin. Place a piece of dry gauze between the skin and the cold pack.
Application of cold to the site is thought to decrease toxicity of the agent to the area. It is believed this causes vasoconstriction, localising the extravasation and perhaps allowing time for local vascular and lymphatic systems to disperse the agent as well as shunting bloodaway from the area and reducing cellular metabolismi,ii,iii,iv. The application of cold to vinca-alkaloid induced injuries has been shownto increase ulcer formation in animal studies and therefore the use of cold should be reserved only for the treatment of non vinca- alkaloid vesicant injuriesi,ii,iii,iv
Intermittent local cooling for up to 24 hours appears to be the recommended scheduleii.The evidence supporting this treatment consists entirely of III or IV reports but is sufficiently extensive that this can be recommended at Grade B.
B. Apply topical hydrocortisone 1% cream every six hours for the next 7 days or for as long as erythema continues.
Many guidelines recommend the use of subcutaneous or intradermal steroids. However many of the reviews found argued that inflammation is not prominent in the aetiologyof tissue necrosisi,ii,iii,iv,v. There is also evidence that subcutaneous or intradermal steroids may be harmful in high dosesi,ii, are ineffective incertain extravasationsii and may increase the skin toxicity of vinca alkaloidsi,ii. Therefore thisguideline recommends that topical hydrocortisone 1% is used, which can do little harm and may bring down non-specific inflammation, except in vinca-alkaloid injuries. The evidence supporting this treatment consists entirely of III or IV reports but is sufficiently extensive that this can be recommended at Grade B.
16
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
C. Infiltrate the site with 1500 units of hyaluronidase in 1ml Water for Injection. Inject subcutaneously at several areas around the circumference of the extravasated area. Gently massage the area to facilitate dispersion.
Hyaluronidase has been reported to be an effective antidote for vinca alkaloids andetoposidei.ii,iii,iv. Animal studies have also shownhyalouronidase to be of potential benefit in paclitaxel extravasations. It is believed injection of hyalouronidase promotes the permeability of tissue, improving the absorption of infiltrated cytotoxic. Tissue injury is decreased secondary to the dilution of the cytotoxic across a larger tissue area. The guideline therefore recommends that the use of hyalouronidase is unlikely to cause harm and recommends its use where a policy of “spread and dilute” is indicated.The evidence supporting this treatment consists entirely of III or IV reports but is sufficiently extensive that this can be recommended at Grade B.
D. Apply heat pack, firmly but without pressure, continuously for 24 hours. The heat pack should not be placed directly on the skin. Place a piece of dry gauze between the skin and the heat pack.
Application of heat is thought to induce vasodilation, which facilitates increased systemic absorption and distribution of the cytotoxic. It is thought to aid the dispersal of the vinca-alkaloids. The application of heat to anthracycline induced injuries increases tissue damage and therefore the use of heat should be reserved only for the treatment of vinca alkaloid and non-vesicant induced injurieswhere a policy of “spread and dilute” is indicatedi,ii,iii,iv.The evidence supporting this treatment consists entirely of III or IV reports but is sufficiently extensive that this can be recommended at Grade B.
E. Apply topical Dimethyl Sulfoxide (DMSO) 50%(v/v), by painting on with a ‘cotton bud’, every 2 hours at the extravasation site for 24 hours. Avoid contact with good skin. If blister forms stop DMSO and seek further advice.
This is recommended for the anthracyclines and mitomycini,ii,iii,vi,vii. The use seems well supported, and seems unlikely to cause any harm. The optimal schedule and duration ofDMSO applications is unclear but should probably be at least every 6 hours for a minimum of 3 daysii. It should be noted that DMSO is not licensed for this use.The evidence supporting this treatment consists entirely of III or IV reports but is sufficiently extensive that this can be recommended at Grade B.
F. For the next 7 days apply DMSO every6 hours, alternating with topical hydrocortisone 1% cream every 6 hours (a preparation applied every 3 hours on an alternate basis). Do not use an occlusive cover. If required cover once the area is dry. If blister forms stop DMSO and seek further advice.
17
The CINs group hereby assert their moral rights tothe works herein in accordance with the Data Protection Act 1988.
Policy review date 01/09/16
10.0 Infiltrate the site with 1-3ml of 3% isotonic sodium thiosulphate into the affected area using multiple ‘pin cushion’ injections at several areas around the circumference of extravasated area. Before administering Sodium Thiosulphate the solution provided in the pack MUST BE DILUTED FIRST. Dilute 1.2ml 50% sodium thiosulphate to 20ml with water for injection
This is recommended for mustinei,ii,iii. The use seems well supported, and seems unlikely to cause any harm. It should be noted that sodium thiosulphate is not licensed for this use.The evidence supporting this treatment consists entirely of III or IV reports but is sufficiently extensive that this can be recommended at Grade B.
G. Monitor patient closely for “recall reactions”.
Anthracyclines administered after radiotherapy have been shown in a reactivation of skin toxicity known as a “recall reaction”. A similar reaction may be seen in patients who have had previous extravasations. This reaction has alsobeen shown with paclitaxelii.The evidence for this approach in patients on anthracyclines and Paclitaxel is very limited (level IV) and the confidence with which it can be recommended is Grade C.
Reproduced with thanks from the UKCCSG paediatric extravasation policy
iPharmacologic Management of Vesicant Chemotherapy Extravasations. Cancer Chemotherapy Handbook. 2nd Edition. Chapter 6. Ed. Dorr R.T., Von Hoff D. Appleton & Lange, Norwalk, Conneticut.
ii Bertelli, G. Prevention and Management of Extravasation of Cytotoxic Drugs. Drug Safety 12(4): 245-255. 1995.
iii Dorr R.T. Antidotes to Vesicant Chemotherapy Extravasations. Blood Reviews 4: 41-60. 1990.
iv Kassner E. Evaluation and Treatment of Chemotherapy Extravasation Injuries. Journal of Paediatric Oncology Nursing 17(3): 135-148. 2000.
v Extravasation of drugs. Anaesthesia Review. Chapter 13. Ed. Kaufman L., Ginsbury R. Churchill Livingstone. 1997. London.
vi Rospond R.M. Utilization of dimethyl sulfoxide for treating anthracycline extravasation. J Oncol Pharm Practice 1(4): 33-39. 1995.
vii Lawrence H.J., et al. Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemotherapy and Pharmacology 23: 316-318. 1989.